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Abstract: 
 
Pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) is one of the most 
lethal tumour types worldwide.  The majority of patients present late with locally 
advanced or metastatic disease. Therefore, despite advances in operative 
techniques, perioperative management and oncological treatments, the overall 5-
year survival remains <5%.  The reason for poor survival is due to disease 
recurrence even after curative surgical resection for small tumours.  Determining 
factors that lead to disease recurrence may help in identifying those with a poor 
prognosis so that treatment options can be tailored to each patient.  We investigated 
whether operative technique, clinicopathological factors or specific genetic mutations 
could influence disease recurrence.  Further, we sought to identify a biomarker in the 
peripheral circulation that could be used as a prognostic marker.  We confirmed that 
a positive medial resection margin and a high frequency of KRAS mutation in the 
tumour tissue result in early disease recurrence.  Further, that the altered expression 
of five microRNAs may be useful as a blood-based prognostic predictor. 
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CHAPTER 1:   
 
An Introduction To Pancreatic Cancer 
 
1.1 DUCTAL ADENOCARCINOMA OF THE PANCREAS 
 
Pancreatic cancer is a devastating and aggressive disease with an extremely poor 
prognosis despite radiological, surgical and oncological advances. The majority of 
cancers are exocrine (90%) arising from the ductal cells and are termed pancreatic 
ductal adenocarcinomas (PDAC). Other rarer types of pancreatic cancer include 
acinar cell carcinomas, mucinous cystadenocarcinomas, sarcomas, lymphomas, 
adenosquamous carcinomas, colloid carcinomas, giant cell tumours, 
pancreatoblastomas, signet ring cell carcinomas, undifferentiated carcinomas and 
neuroendocrine tumours.  Evidence suggests that PDAC is a slowly developing 
disease, with at least fifteen years between the initiating mutations and the potential 
for metastatic spread1. By the time of diagnosis, it is considered to be an invasive 
and progressive disease, which is highly resistant to chemotherapeutic agents. Our 
understanding of its tumour biology continues to rapidly improve, however 5-year 
survival remains at only around five per cent. Surgical resection is the only potentially 
curative treatment; however this is only possible in up to 25% at initial diagnosis. 
Those with advanced disease who are treated with palliative chemotherapy and no 
surgery have a median survival of just 6 months.2 Even those with a curative R0 
resection only have a median survival of ~29 months.3  
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1.2 EPIDEMIOLOGY 
 
The GLOBOCAN project, led by the International Agency for Research on Cancer 
and the World Health Organisation 4 estimates that worldwide there are 337,872 new 
cases of PDAC diagnosed each year.  The cumulative risk of developing the disease 
before the age of 75 is 0.47 for every 100 children born, which is increased in more 
developed regions (0.85) compared to less developed regions (0.31).   Although it 
only accounts for 3% of new cancer cases, mortality is closely related to incidence 
and it is the fourth leading cause of cancer death among both males and females 
(National Cancer Institute, September 2010)).  Age-standardised rates are higher in 
males compared to females and in those of White and Black ethnicity compared to 
Asian (Cancer Research UK, June 2014). 
 
1.3.1 RISK FACTORS AND SCREENING 
 
Pancreatic cancer can be divided into sporadic and familial cancer.  There are four 
main genes affected in sporadic cancer: KRAS (95% of tumours); CDKN2A (p16) 
(90%); p53 (75%); and SMAD4 (55%).5  Multiple genetic and epigenetic mutations 
interlinked with environmental factors will lead to the development of PDAC.  As with 
many cancers, the major risk factor is age, with the majority of cases occurring after 
the age of 60, and very few before 40. Some other identified risk factors include:  
Smoking; chronic pancreatitis; diabetes; obesity; other medical conditions; diet; and 
ABO blood type.  A common feature of these risk factors is an ability to induce 
oxidative stress and thus DNA damage.6  The resultant increase in reactive oxygen 
species (ROS) causes damage to lipids, protein and DNA.  Mechanisms exist at the 
cellular level to repair damaged DNA and to neutralise ROS.  Activation of these 
repair pathways is seen in pancreatic cancer cell lines and in tumour cells. 7, 8  
Certainly, there is an increased level of direct DNA damage in patients with 
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pancreatic cancer. 9  Familial pancreatic cancer is seen in patients with a first degree 
relative also affected and in younger patients.  However, there is no standardised 
classification for these patients, such as with the Amsterdam criteria in familial 
colorectal cancer.  In these cases of familial aggregation of PDAC, the PRSS1, 
SPINK1, CDKN2A, STK11, ATM, BRCA1, BRCA2, PALB2, APC  and mismatch 
repair genes may be involved. 
 
1.3.2 Sporadic pancreatic cancer:  
Smoking: Current tobacco use is the single most important risk factor for pancreatic 
diseases, accountable for a quarter of cases.  Results would suggest that smoking 
causes a 75% increase in the risk of pancreatic cancer with a higher risk in those 
who smoke more per day and for a longer duration.  The risk persists for at least 10 
years.10  Analysing 51 population based studies with nearly 3 million participants, 
ever smokers have a relative risk (RR) of developing PDAC of 1.60 compared to 
never smokers. 11  The relative risk is more in current smokers: RR 1.74 (95% CI 
1.61-1.87) than in former smokers: RR 1.2 (95% CI 1.11-1.29) 10.  In addition, 
cigarette smokers have an increased risk compared to pipe and/or cigar smokers.10  
Tobacco carcinogens may reach the pancreas via the bloodstream as with other 
smoking-related cancers, or directly via bile, which may explain the high incidence of 
head of pancreas cancers.  However the pathological mechanisms behind the 
development of cancer is not well understood.  Indeed, tobacco consumption does 
not appear to be associated with an increased frequency of K-ras mutations12 
suggesting earlier epigenetic changes. 
Chronic Pancreatitis: Chronic pancreatitis (CP) is a progressive inflammatory 
condition with an incidence of 3.5-10 per 100,000 population.13  It is characterised by 
irreversible morphological changes resulting in loss of both exocrine and endocrine 
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pancreatic function.  Histopathologically we see chronic inflammation, loss of acinar 
cells, irregular inter-lobular fibrosis, distorted ducts and patches of resolving fat 
necrosis.14  Mice with mutant K-ras expression show pancreatitis in the early stages 
and cerulein injections (a cholecystokinin analogue which hyperstimulates the 
pancreas, inducing pancreatitis) accelerates the progression to advanced cancer in 
these mice.15  The correlation is also seen in humans with a recent 15 year cohort 
study of nearly 12,000 patients with chronic pancreatitis finding an increased risk for 
pancreatic cancer compared to controls, with an adjusted hazard ratio of 6.9 (95% CI 
5.6-8.6).16  Meta-analyses of case-control and cohort studies have also found an 
increased risk of pancreatic cancer in those with CP, with a RR of 5.1 (95% CI 3.5-
7.3).17  The risk is more pronounced in the first 2-4 years from the diagnosis of CP16, 
18 and also in those with tropical pancreatitis.17 There is debate in the literature as to 
whether the risk is increased in those with alcoholic CP compared to those with CP of 
other aetiology16, 19.  It is possible that inflammatory insults can hyperstimulate 
mutated K-ras allowing the initiation of the sequence of carcinogenesis.20  There are 
certainly altered cytokine levels in patients with pancreatic cancer compared to 
controls and these may have a causative function.21 
Diabetes; It has long been recognised that type II diabetes may increase the risk of 
developing PDAC, it is seen to be both a cause and a consequence of cancer. There 
does not seem to be the same relationship for type I diabetics22 however, the majority 
of studies have not distinguished between the two types. A meta-analysis of over 
9000 patients with pancreatic cancer found an 80% greater risk of pancreatic cancer 
in those with type II diabetes. 23 However, the RR of developing cancer appears to be 
increased in those with a shorter duration of disease suggesting some of the effect 
may be due to an early manifestation of the tumour. Although, there does remain 
some evidence for a causal relationship between diabetes and pancreatic cancer as 
a 50% increased risk still exists for those with a >10 year history of diabetes.24 
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Furthermore, there is a dose-response pattern with an increased level of fasting 
glucose increasing cancer risk.25 26 In type II diabetes, the pancreas is exposed to 
high levels of insulin for many years and develops insulin resistance. It is postulated 
that this may be involved in the development of pancreatic cancer. Certainly, PDAC 
cell lines have insulin receptors and insulin increases PDAC cell proliferation in a 
dose-dependent manner.27 This suggests that insulin may be important in tumour 
growth. Insulin also increases production of Insulin-like Growth Factor 1 which 
promotes cell growth and inhibits apoptosis in human pancreatic cancer cells.28 
Interestingly, diabetic medication and their pharmacological effects may also have a 
role in tumourigenesis with a reduced risk of PDAC seen in type II diabetics taking 
metformin.29 Glucagon-like-peptide-1 (GLP-1) may cause proliferative effects on the 
exocrine pancreas30 with some concerned that this increases the risk of cancer 
although, others have seen apoptosis of pancreatic cancer cell lines with inhibition of 
tumour growth following activation of the GLP-1 receptor31. This remains a 
controversial topic however most agree that the cardiovascular benefits of using 
GLP-1 drugs in diabetes far outweighs a potential but poorly reported risk of 
cancer32. 
Obesity: There is increasing evidence suggesting that adiposity, measured as the 
body mass index (BMI) may increase the risk of developing pancreatic cancer. Two 
large meta-analyses analysing 3.5 million people with 8062 cases of PDAC33 and 5 
million people with 9504 cases of PDAC34 have been conducted within the last 
decade. The RR of developing PDAC per unit increase in BMI was 1.12 (95% CI, 
1.06–1.17) in the first and 1.10 (95% CI: 1.07–1.14) per 5-unit increase in the second 
study. A dose-response effect is seen with the highest risk in those with a BMI>30. 
The majority of the studies analysed controlled for the confounding factors smoking 
and diabetes and found no difference when taking gender into account. Adipose 
tissue is involved in free fatty acid metabolism and cytokine release,35 resulting in an 
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increase of fatty acids and tumour necrosis factor-α and reduced release of 
adiponectin.36 This leads to hyperinsulinaemia and a reduced insulin tolerance 
thereby stimulating cell growth as mentioned above. A Furthermore predisposing 
factor for cancer is pancreatic duct replication, which is increased tenfold in obese 
compared to lean people37. In addition, increased adiposity increases lipid 
peroxidation38 which may cause DNA damage. 
Other medical conditions: There are some suggestions that other pathologies 
increase the risk of pancreatic cancer. For example, patients with pancreatic cancer 
are more likely to be H. Pylori positive.39 Although it is not clear whether this is 
reverse causality, it is hypothesised that excess acidity is associated with basal 
stimulation of pancreatic bicarbonate production, which may increase ductal 
hyperplasia and increased DNA synthesis.40 Patients with inflammatory bowel 
disease (IBD), both Crohn’s disease and Ulcerative Colitis, have an increased life-
time risk of many gastrointestinal and extra-intestinal cancers,41 including pancreatic 
cancer. This risk is further increased in IBD patients with associated primary 
sclerosing cholangitis.42 Furthermore, patients who have Hepatitis B have an 
increased risk of pancreatic cancer (odds ratio for developing pancreatic cancer in 
those positive for hepatitis B surface antigen (HBsAg) is 1.50 (95 % CI 1.21 to 
1.87),43 and those with Hepatitis C virus may also have an increased risk44, although 
the association is less clear. Lastly there may be a link between periodontal disease 
and pancreatic cancer.45 
Diet: A meta-analysis of eleven prospective studies analysed red and processed 
meat consumption in 2,307,787 participants with 6643 cases of pancreatic cancer. 
The RR of pancreatic cancer for a 50g per day increase in processed meat 
consumption (about one serving) was 1.19 (95% CI 1.04-1.36), resulting in a 19% 
increased risk.46 With regards to red meat, the overall RR showed no increased risk 
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with pancreatic cancer with an increase of 120g per day of red meat consumption.  
However, an association was seen in males, but not females. Importantly, not all 
studies controlled for the confounders obesity and diabetes and there is 
heterogeneity among studies in terms of meat classification and length of time for 
meat consumption. In theory, processed meats could increase the risk of cancer as 
they contain N-nitroso compounds, which can induce pancreatic cancer in animal 
models.40 Other case-control studies have suggested a diet high in protein and 
unsaturated fatty acids is associated with a decreased risk of pancreatic cancer, in a 
dose-dependent fashion.47 There is Furthermore limited evidence to suggest a 
decreased risk of cancer with a consumption of fruit and vegetables and whole grains 
whilst a possible increased risk exists with the consumption of sugar-sweetened soft 
drinks.48 Finally, conflicting evidence is found regarding vitamin D, with some 
supporting a reduced risk of cancer49 and others a higher risk,50 with high levels of 
vitamin D. 
ABO Blood type: There is some evidence to suggest that ABO blood type may affect 
risk for pancreatic cancer. In a Chinese population an increased risk of cancer was 
seen in those with blood group A compared to blood group O. On meta-analysis of 
world-wide studies, there is also an increased risk with groups B and AB compared to 
O.51 It is possible that there are ABO-related differences in inflammation and cytokine 
production but these theories are not well supported. 
1.3.3 Familial pancreatic cancer: 
Around 5-10% of cases of pancreatic cancer are seen to show familial clustering, 
with an elevated risk of pancreatic cancer in individuals with a first degree relative 
affected. The incidence of pancreatic cancer is estimated to rise from 9 per 100,000 
per year in patients with no family history of PDAC, to 288 per 100,000 per year in 
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those with three or more first degree relatives with pancreatic cancer.52 A number of 
germline mutations have been identified in these familial cases of pancreatic cancer.  
PRSS1 and SPINK1: Hereditary pancreatitis increases the risk of developing PDAC. 
The highly penetrant autosomal dominant disorder, which usually manifests by the 
age of 30,53 is associated with mutations in PRSS1, which encodes for the protein 
trypsinogen. Acute pancreatitis is caused by premature activation of trypsinogen with 
recurrent attacks of acute pancreatitis leading to chronic pancreatitis and its 
increased cancer risk. The lifetime risk of PDAC in these patients is 35 fold by 70-75 
years of age.54 The autosomal recessive form of hereditary pancreatitis develops due 
to SPINK1 mutations. This gene encodes a trypsin inhibitor and its mutations 
therefore lead to inappropriate trypsin activity, again resulting in pancreatitis.55 
CDKN2A: Another autosomal dominant disorder which has a 20% increased risk of 
pancreatic cancer by the age of 75, as well as a 60-90% risk of melanoma, is the 
Familial atypical mole and multiple melanoma (FAMMM) syndrome. These patients 
have abnormalities in CDKN2A. The mutant p16 proteins cannot inhibit the cyclin 
D1/CDK4 or cyclin D1/CDK6 complex, leading to genomic instability and uncontrolled 
cell division.56  
STK11 (LKB1) and ATM: Germline mutations in STK11 are associated with Peutz-
Jeghers, an autosomal dominant condition resulting in early onset, large, multiple 
small intestinal and colonic polyps with an increased cancer risk at these sites.57 
These patients also have a 26% increased risk of pancreatic cancer.58 The 
STK11/LKB1 gene encodes for a member of the serine/threonine kinase family, 
which functions as a tumour suppressor59. The protein encoded by the ATM gene is 
also a serine/threonine kinase. It is involved in the DNA damage response signaling 
pathway60, thus integral to the maintenance of genomic stability. Mutations in ATM 
result in the disease ataxia-telangiectasia characterized by cerebellar ataxia, 
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oculomotor apraxia, frequent infections, telangiectasias of the skin and conjunctivae 
and an increased rate of neoplasia, particularly haematological malignancies.61 
These mutations have also been linked to pancreatic cancer.62 
BRCA1, BRCA2 and PALB2: These three genes encode proteins important in DNA 
repair pathways required to halt the development of cancer. Certain endogenous and 
exogenous agents may cause double-stranded DNA breaks. Protein complexes 
involving products coded by these genes form, enabling firstly recognition, and 
secondly repair of these breaks by performing exonucleolytic resection of one strand 
of DNA followed by replication of the single-stranded DNA.54 People with mutations in 
BRCA1 and BRCA2 carry an 80% lifetime risk for the development of breast cancer63 
and germline mutations in PALB2 are also associated with hereditary breast 
cancer.64 Those with a BRCA2 mutation also have a 3.5 fold increased risk of 
pancreatic cancer65 and this germline mutation is the most common recognizable 
cause of familial pancreatic cancer. The risk of pancreatic cancer in BRCA1 mutation 
carriers is less clear with some reporting a RR OF 2.366 whilst others have found no 
association.67 Genome sequencing of pancreatic cancer identified PALB2 as a 
mutation in 1-3% of pancreatic cancer families.68, and carriers have a 5.9 fold 
increased risk of pancreatic cancer.69 
APC and Mismatch repair genes: Mutations of the APC gene are well known to result 
in familial adenomatous polyposis (FAP) and those in a number of mismatch repair 
genes (e.g. hMLH1, hMSH2, hMSH6, and hPMS2) predispose to hereditary non-
polyposis colon cancer (HNPCC). As well as a 100% and 80% risk of developing 
colon cancer respectively, these patients also have a risk of extra intestinal cancers. 
HNPCC patients have a 3.7% risk of pancreatic cancer whilst those with FAP may 
have a 4 fold increased risk, although others have failed to demonstrate this.70  
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1.3.4 Screening: 
Considering that an earlier diagnosis of pancreatic cancer increases the likelihood of 
resectable disease prior to the development of mestatases1 and thus improved 
prognosis, there has been interest in screening for pancreatic cancer amongst the 
high risk groups discussed above. The International Cancer of the Pancreas 
Screening (CAPS) recently developed and published consortium statements 
regarding the management of patients at risk of familial pancreatic cancer.71. A 
screening programme should detect T1N0M0 PDAC and high-grade dysplastic 
precursor lesions to enable curative R0 resections. There was agreement that there 
was a role for screening with endoscopic ultrasonography (EUS) and/or magnetic 
resonance cholangiopancreatography (MRCP) of the pancreas in the following 
patients: Those with first degree relatives from a pancreatic cancer family (i.e. a 
family member with PDAC has at least two affected first degree relatives); and 
patients with Peutz-Jegher’s, HNPCC, BRCA2 mutations or CDKN2A mutations with 
at least one first degree relative affected. However, age and screening intervals were 
not agreed upon and Furthermore, consensus was not reached on which 
abnormalities should lead to surgical resection. Before a screening programme can 
be initiated, Furthermore advancement to improve the sensitivity and specificity of 
screening methods and international consensus is warranted. 
 
1.4 PRECURSOR LESIONS 
 
There are three types of precursor lesions in PDAC that follow a multi-step 
progression from neoplasia showing mild dysplasia to invasive cancer. They are: 
Pancreatic Intraepithelial Neoplasia (PanIN); Intraductal Papillary Mucinous 
Neoplasm (IPMN); and Mucinous Cystic Neoplasm (MCN). Some of these lesions 
may be detected on imaging, often incidentally, and either resected or kept under 
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surveillance to prevent the development of, or to allow early detection of, invasive 
carcinoma. 
 
PanIN: PanINs are microscopic proliferative epithelial lesions in the small calibre 
pancreatic ducts and ductules, usually involving ducts <5mm in diameter.72 They are 
the most common precursor lesion recognised in pancreatic cancer and often found 
surrounding PDAC at histological analysis of surgical resections. A four-tier 
classification system was established in 201073 that grades the histopathological 
findings. PanIN-1 lesions show metaplasia and ductal hyperplasia and are 
subdivided into flat (PanIN-1A) and papillary (PanIN-1B) types. PanIN-2 lesions are 
papillary ductal lesions with atypia, low-grade or moderate dysplasia, and show 
nuclear abnormalities including loss of polarity, nuclear crowding, enlarged nuclei 
and hyperchromatism. PanIN-3 lesions show severe dysplasia, intraductal carcinoma 
and carcinoma-in-situ. The immunohistochemical characteristics of PanINs vary with 
degree of dysplasia. For example, the apomucin MUC5AC, which is not expressed in 
normal pancreatic ducts, is expressed in all PanINs. MUC3 and MUC4 show a 
progressive increase in expression with increasing dysplasia, and MUC1 is 
expressed almost exclusively by high grade PanIN and invasive carcinoma.74 
 
Carcinogenesis is thought to follow a step-wise approach from low-grade PanIN to 
high-grade PanIN to invasive carcinoma. With each step, certain genetic and 
epigenetic abnormalities have been found and the accumulation of mutations will 
result in PDAC (Figure 1). Telomere shortening is one of the earliest events in 
tumourigenesis and seen almost universally in PanINs, including those of low-
grade.75 Telomeres prevent fusion between the ends of the chromosomes, providing 
a protective effect, and their shortening occurs with age and number of cell divisions. 
The shortened telomeres cause chromosomal instability and promote neoplastic 
progression.76 Kirsten rat sarcoma (KRAS) mutations are also an early event. 
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Mutations in this oncogene are present in 90-95% of PDAC specimens and thought 
to be the driver mutation for PDAC. PanINs also demonstrate alterations in tumour 
suppressor genes known to be associated with PDAC including: p16/CDKN2A, 
inactivated in intermediate and late lesions (PanIN-2/3); and p53, SMAD4 and 
BRCA2 genes inactivated in PanIN-3 lesions. 77 Epigenetic abnormalities in cancer 
are mostly due to methylation of the gene promoter region CpG islands, resulting in 
transcription silencing.78 The hypermethylation of tumour suppressor genes is 
thought to be involved in carcinogenesis. Indeed, as many as 70% of PanIN-1A 
lesions demonstrate abnormal promoter methylation. 79  
 
Unfortunately PanINs are not detectable by radiological imaging and thus early 
detection with preventative and curative resection prior to the development of 
carcinoma is not yet possible. Furthermore, if a PanIN is detected at intraoperative 
frozen section it remains unclear what the best management should be. Some would 
suggest further resection with PanIN-3 lesions but not with PanIN-1 and PanIN-2 
lesions.80 
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Figure 1 - Molecular changes during progression of pancreatic cancer.  Normal duct epithelium progresses to 
infiltrating carcinoma through a series of histologically defined precursors, pancreatic intraepithelial neoplasia 
(PanINs). PanINs are classified into early and late lesions, starting with PanIN-1A, 1B (hyperplasia) and progressing 
to PanIN-2 and then to PanIN-3 or carcinoma in situ. The associated genetic alterations at each stage are shown 
below.  Reproduced from81. 
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IPMN: IPMNs are cystic lesions arising in the main duct or branch duct epithelium of 
the pancreas characterised by papillary proliferation and mucin production. They are 
classified according to their malignant transformation from those with low-grade 
dysplasia, intermediate-grade dysplasia, high-grade dysplasia to those IPMNs with 
invasive carcinoma (IPMC). They are also divided into three types based on 
anatomical location: main-duct IPMN (MD-IPMN); branch duct IPMN (BD-IPMN) and 
mixed type IPMN (mixed IPMN) where both main and branch ducts are involved. 
Subtypes of IPMN based on their histological and immunohistochemical analysis of 
MUC expression and the intestinal marker CDX-2 are also apparent.82  
 
Genetic changes in the genes known to be involved in PDAC have been 
demonstrated in IPMNs, namely alterations in KRAS, p16/CDKN2A, p53 and SMAD4. 
Indeed >96% of IPMNs have a GNAS or KRAS mutation with more than half having 
both83 indicating that the activation of G-protein signalling plays an important role in 
IPMN. However, these changes appear to happen early in the development of IPMN 
and it is as yet unclear what genetic changes differentiate between low-grade 
dysplasia and high-grade dysplasia or IPMC.  
 
IPMNs can be detected on computed tomography (CT) scans, magnetic resonance 
imaging (MRI) scans and at endoscopic ultrasound (EUS) of the pancreas. Analysis 
of cyst fluid CEA, taken at EUS, can further differentiate between cystic lesions. A 
CEA >192 ng/ml can detect mucin producing cysts (IPMNs and MCNs) with 80% 
accuracy.84 The increased use and improvements in these imaging modalities has 
resulted in an increased detection of IPMNs as an incidental finding. Whilst we do not 
want to over-treat benign cysts with pancreatic resection, there is a risk of disease 
progression to carcinoma and management decisions must therefore be discussed at 
a pancreatic multidisciplinary team (MDT) meeting. The International consensus 
guidelines for the management of IPMNs revised in 2012,85 recommends separate 
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management strategies for those with MD-IPMN / mixed IPMN and those with BD-
IPMN. The risk of progression to cancer for MD-IPMN is 36-90%.86 87 and surgical 
resection is thus recommended in those with a main pancreatic duct diameter of ≥10 
mm or for those with a main pancreatic duct diameter of 5-9mm with one of: a 
thickened IPMN wall; intraductal mucin; or mural nodules. For BD-IPMNs the risk of 
developing an invasive carcinoma has been reported to be as low as 6%88 and 
therefore annual surveillance of these lesions is recommended. Resection of BD-
IPMNs is indicated when there are ‘worrying features’ including: cyst size >3cm; a 
non-enhancing mural nodule; thickened cyst wall; and/or an abrupt change in the 
caliber of the main pancreatic duct. 
 
MCN: These are mucin-producing cystic lesions of the pancreas characterised by the 
presence of ovarian type stroma. The epithelial lining consists of columnar cells and 
they are classified according to the degree of dysplasia (low-grade; intermediate-
grade and high-grade). They are almost always solitary and of incidental finding in 
young people and located in the body or tail of the pancreas. MCNs are identified on 
the imaging modalities discussed above and also have a high CEA in the cyst fluid. 
However, they can be distinguished from IPMNs based on a lack of communication 
with the main pancreatic duct.89 Although the molecular changes in MCN have not 
been as well researched as the other precursor lesions, due to their lower incidence, 
mutations have been found in KRAS, p16/CKDN2A, p53 and SMAD4 with an 
average of 16 +/- 7.6 mutations for each MCN, compared with 27 in IPMN.90 
However, unlike in IPMN, GNAS mutations have not been demonstrated. 3.9%- 30% 
of MCNs will progress to an invasive cancer, usually PDAC,91, 92 and thus surgical 
resection of MCNs is recommended. 
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1.5 GENETICS OF PANCREATIC CANCER 
 
In 2008, an extensive land-mark study characterised the complex genetic network of 
PDAC by performing whole-exome sequencing of 24 tumours investigating 20,661 
genes. This revealed that PDAC contains an average of 63 genomic alterations, 
mostly point mutations. 93 They identified 12 core signalling pathways and processes 
which are genetically altered in the majority of pancreatic cancers and are thought to 
drive PDAC tumourigenesis. These are: TGF β signaling; JNK signaling; integrin 
signaling; WNT/notch signaling; hedgehog signaling; control of G1/S phase 
transition; apoptosis; DNA damage control; small GTPase signaling; invasion; 
hemophilic cell adhesion; and KRAS signaling. Furthermore pathways have since 
been recognised including axon guidance and chromatin regulation. 94 95 There are 
four genes which are most commonly affected in PDAC including KRAS, CDKN2A, 
TP53 and SMAD4. 
 
KRAS: KRAS is a member of the RAS family of oncogenes and encodes for 
membrane-bound GTPases involved in regulating signal transduction.96 The most 
common mutation is one amino-acid substitution in position 12 of the KRAS protein 
leading to a glycine to aspartic acid change. 97 Mutations have also been seen in 
codons 13 and 61. The mutations lead to constitutive activation of RAS hindering the 
ability of RAS to hydrolyse GTP to GDP.98 This activation causes persistent 
stimulation of the downstream signalling pathways including phosphatidylinositol 3-
kinase (PI3K)/AKT pathway, the RAF/MEK/ERK pathway and nuclear factor κB,99, 100 
resulting in increased cell proliferation, altered metabolism, apoptosis suppression, 
evasion of the immune response and metastasis.97 
 
The association of pancreatic cancer with mutated KRAS was established some 
years ago.101 102 More recently, exome sequencing established KRAS as the most 
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commonly mutated gene in PDAC, seen in 90-95% of cases.95 It is seen as the driver 
mutation involved in the initiation or early phase of tumourigenesis.105 The 
association between mutant KRAS and PDAC is supported by mice models. Mice 
with a mutant KRAS in codon 12 are born with a normal pancreas at birth but shortly 
develop PanINs progressing in grade and number with progression to invasive 
cancer in older mice.103 Other mouse models have been developed which are 
defined by tissue-specific, temporally regulated and reversible expression of 
KRAS.104 The induction of KRAS in these mice leads to precancerous lesions and its 
inactivation leads to regression of the lesions.104 Furthermore, silencing of KRAS in 
mouse PDAC xenografts using a small interfering RNA (siRNA) reduces tumour 
growth and improves sensitivity to gemcitabine therapy.105 Evidence that mutant 
KRAS initiates PDAC but is also required for tumour survival and chemotherapy 
resistance. The importance of a KRAS inhibitor for PDAC therapy is evident however, 
as yet, an effective agent to block the binding of KRAS to GTP has not been 
developed. The majority of agents developed are designed to block downstream 
signaling pathways such as sorafenib targeting the RAF/MEK/ERK pathway and 
various agents targeting the MAPK pathway at MEK, the PI3K pathway and the AKT 
pathway. However, clinical trials have so far shown little benefit 106 107 108, perhaps 
due to complex feedback loops between the many pathways with deactivation of one 
leading to increased activation of another. 
 
CDKN2A: The tumour suppressor gene CDKN2A, located on chromosome 9q21.3, 
encodes for the p16 protein, which is a regulator of the cell cycle at the G1/S 
checkpoint. It inhibits cyclin D/CDK4/6 complex, which in turn inhibits retinoblastoma 
protein phosphorylation and prohibits progression from G1 phase to S phase thus 
arresting cell proliferation.109 Loss of p16 function is seen in >90% of PDACs.110 
Although mice with a deletion of p16 do not develop PDAC,111 mice expressing 
mutant KRAS and a p16 deletion show a highly invasive tumour with high rates of 
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epithelial-to-mesenchymal transition (EMT).112 More recently, Furthermore evidence 
has shown that an expression of mutant KRAS and the silencing of p16 expression in 
a human pancreatic epithelial nestin-expressing (HPNE) cell line induces 
tumourigenic transformation in vitro.113 The transformed cells show increased cell 
proliferation and increased invasion with an up-regulation of EMT markers. In an 
orthotopic mouse model, the transformed cells exhibit increased tumour growth in 
vivo.113 This suggests that tumours with both KRAS mutation and p16 deletion play 
important roles in the tumourigenesis and invasiveness of PDAC. 
 
TP53: The TP53 tumour suppressor gene is located on chromosome 17p13.1 and 
encodes for the p53 protein. It induces cell cycle arrest or apoptosis in damaged cells 
but is inactivated in 50-75% of PDACs.114, 115 Functional loss of p53 enables cellular 
survival and division in the presence of DNA damage furthermore facilitating genetic 
mutations and instability.114, 116 Certainly mice with mutant KRAS and loss of p53 
develop an invasive and metastatic PDAC, demonstrating a high degree of genetic 
instability.117 Furthermore, the combined loss of p53 and autophagy (a lysosomal 
recycling process essential for tissue or cell homeostasis) promotes progression from 
PanIN to carcinoma and alters cellular metabolism enabling rapid tumour growth.118 
 
SMAD4: SMAD4 encodes a member of the Smad family of signal transduction 
proteins. These are phosphorylated and activated by transmembrane serine-
threonine receptor kinases in response to TGF-beta signaling. Deletion of SMAD4 
results in: increased TGF-beta signaling resulting in abnormal gene expression and 
transcription regulation; loss of SMAD4-dependent cell growth inhibition; and 
increased EMT.119 Loss of SMAD4 is seen in 55-60% of PDACs.120 Mice with mutant 
KRAS and loss of SMAD4 develop a far more rapid progression to PDAC compared 
to mice with mutant KRAS alone.121 Furthermore, inactivation of SMAD4 enhances 
EGFR and CD133 expression, whereas re-expression of SMAD4 suppresses EGFR 
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and CD133 levels in PDAC cells. Overexpression of EGFR and CD133 has been 
associated with tumour malignancy, invasiveness and decreased survival.122 123 
SMAD4 loss of function almost always occurs in association with genetic inactivation 
of TP53, whereas TP53 inactivation does not, indicating SMAD4 alterations are 
selected for in association with TP53 genetic alterations. This relationship also 
suggests that SMAD4 inactivation occurs later than TP53 inactivation in the genetic 
progression model of pancreatic carcinogenesis.124 
 
It is now clear that these four genes (KRAS, CDKN2A, TP53 and SMAD4) contribute 
to the carcinogenesis of PDAC. There are also many genes seen mutated in <20% of 
PDACs including oncogenes such as BRAF, MYB, AKT2 and EGFR; and tumour 
suppressors such as MAP2K4, STK11, ACVR1B, ACVR2A, FBXW7 and EP300.76, 
125-127 It is likely that a complex mix of differing sequential mutations are required for 
the development of PDAC enabling multiple changes in the signal transduction 
pathways outlined above. However, many of the exact mechanisms underlying the 
transformation to PDAC remain unknown. Furthermore, it is not yet clear whether 
certain mutations, or combination of mutations, result in a poorer prognosis, a 
question which this thesis will attempt to answer. 
   
1.6 CLINICAL DIAGNOSIS OF PDAC 
 
Around 65% of PDAC lesions are seen in the head of the pancreas (HOP) with 15% 
in the body and tail and the remainder diffusely involving the gland.128 Unfortunately, 
wherever the anatomical location of the lesion, early pancreatic cancer is usually 
asymptomatic resulting in delayed detection. Symptoms tend to manifest once the 
tumour has invaded surrounding tissues or metastasised to other organs thus most 
people already have advanced disease at diagnosis.129 The most common 
presenting symptoms reported are: abdominal pain, usually in the upper abdomen 
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which may radiate to the back, experienced by 80% of patients;130 obstructive 
jaundice reported in 16-85%, in those with HOP tumours;131 and weight loss in up to 
79% due to anorexia, malabsorption secondary to pancreatic ductal obstruction and 
cachexia. Some would argue that weight loss is often overlooked until other 
symptoms are apparent and suggest early upper abdominal imaging in patients with 
unexplained weight loss to detect any pancreatic lesions.132 Courvoisier’s sign, 
defined as the presence of a non-tender palpable gallbladder and painless jaundice, 
implies a diagnosis of pancreatic or biliary malignancy rather than gallstones. 
Diabetes or impaired glucose tolerance can also occur due to damage to the 
pancreatic parenchyma. This is a common disease however older patients with a 
new diagnosis of diabetes and significant weight loss should be investigated for 
pancreatic cancer. Furthermore, obstruction of the pancreatic duct by the tumour 
may lead to acute pancreatitis. Another sign of PDAC is Trousseau’s syndrome 
characterised by deep or superficial venous thrombosis, hypercoagulability and 
migratory thrombophlebitis. This syndrome is not exclusive to PDAC, seen also with 
lung malignancies and gliomas. Rarer symptoms reported include loss of taste, skin 
changes and psychological disturbances, namely depression.131 
 
Where there is a suspicion for pancreatic cancer, Furthermore investigations must be 
urgently undertaken. This involves blood tests including tumour markers and 
radiological imaging. Routine blood tests are fairly non-specific but may reveal 
anaemia, hyperglycaemia or raised liver function tests either as an obstructive picture 
from the primary tumour obstructing the common bile duct, or secondary to liver 
metastases. In the clinical setting of pancreatic cancer, the most commonly used and 
validated tumour marker is carbohydrate antigen 19-9 (CA 19-9). CA 19-9 is 
expressed on the surface of cancer cells as a glycolipid and as an O-linked 
glycoprotein.133 It is a Lewis blood group antigen of the MUC1 protein, which is 
commonly expressed in tumours of the upper gastrointestinal tract and may be 
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elevated in patients with pancreatic cancer. As CA 19-9 can only be expressed in 
patients belonging to the Le (α-β+) or Le (α + β-) blood groups, 5-10% of the 
population with the Le (α-β-) phenotype are unable to synthesise it leading to false 
negative results133. Furthermore limitations include a considerable number of false 
positive results due to its elevation in other malignancies such as colorectal, liver, 
breast and lung cancers, as well as in benign diseases including, importantly, 
hyperbilirubinaemia and pancreatitis as well as in liver cirrhosis and lung disorders.134 
CA 19-9 also lacks sensitivity for early pancreatic cancers, <3cm in size,135 and has a 
lower expression in poorly differentiated cancers.135 A recent meta-analysis of 2,316 
patients, found CA 19-9 to have a pooled sensitivity of 0.803 (95 % CI 0.777–0.826) 
and a pooled specificity of 0.802 (95 % CI 0.780–0.823).136 Interest has been 
renewed however in the prognostic value of this marker following some studies 
demonstrating that elevated levels are an independent predictor for poor survival and 
low resectability rates.137-140 
 
Radiological imaging of the pancreas is indicated to aid diagnosis and staging of 
PDAC and may include computed tomography (CT), endoscopic ultrasound (EUS) 
with or without fine needle aspiration (FNA), magnetic resonance imaging (MRI) 
and/or positron emission tomography (PET). Pancreatic cancer is staged according 
to The American Joint Committee on Cancer (AJCC) TNM staging system (Table 1). 
Patients are also staged clinically according to resectability, which dictates the most 
appropriate initial management141 (Table 2).  
 
An ultrasound (US) scan of the pancreas may be performed as part of the initial 
work-up for abdominal symptoms however, this imaging modality is unable to 
definitively diagnose and stage patients thus a tri-phasic multi-slice pancreatic 
protocol CT is the gold standard investigation. This involves imaging 20-25 seconds 
(the arterial phase), 35-40 seconds (the pancreatic or late arterial phase) and 60-80 
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seconds (the portal venous phase) after administration of an intravenous contrast 
medium. The greatest pancreatic parenchymal enhancement is seen in the late 
arterial phase with maximum arterial enhancement observed in both the arterial and 
late arterial phase, depending on the rate of contrast administration142.  Superior 
opacification of the superior mesenteric and portal veins is seen in the portal venous 
phase142. Therefore a CT with this protocol shows good images of the pancreas as 
well as the coeliac axis, superior mesenteric artery (SMA) and superior mesenteric 
and portal veins enabling accurate clinical staging and preoperative planning. Indeed, 
a meta-analysis involving 959 patients who had a CT performed for suspected PDAC 
showed that it diagnosed pancreatic cancer with a sensitivity of 91% and specificity 
of 85%.143 CT is not able to detect lesions at a very early stage or distinguish 
between benign and pre-malignant lesions.144 Furthermore, accuracy for assessing 
resectability is poorer with a sensitivity of 81% and specificity of 82%143 due to 
undetected subtle vascular invasion and small metastases in the liver and 
peritoneum which only become apparent at operation.  
 
EUS-FNA is accurate at confirming solid pancreatic lesions cytologically and has 
become an important part of PDAC assessment in hepatobiliary centres. High 
resolution images of the main pancreatic duct and surrounding parenchyma can be 
achieved so that structures as small as 2-3 mm can be identified. EUS has good 
parenchymal resolution enabling a diagnostic sensitivity of 98%.145 It is superior to 
CT for diagnosing small tumours <3cm,145 for T staging, for observing vascular 
invasion at the spleno-portal confluence,146 and for assessing involvement of the 
coeliac axis, which indicates unresectable disease. Indeed, CT scanning can be 
falsely negative for vascular invasion in approximately 20% of PDAC patients.147 EUS 
also has a negative predictive value approaching 100%148 rendering it extremely 
useful for excluding PDAC in benign lesions with inconclusive findings at CT. This 
radiological modality is indicated in addition to CT for the following reasons: To 
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provide a cytological diagnosis of PDAC in unresectable cases diagnosed at CT prior 
to commencing oncological therapy; for differentiation between malignant and 
inflammatory lesions; when there are doubts as to the type of malignancy where 
alternative diagnoses would follow different management strategies; and for help in 
the characterisation of pancreatic cystic lesions. 
 
Although CT and EUS-FNA are most frequently used for the assessment of 
pancreatic cancer, there may also be a role for MRI imaging of the pancreas and for 
PET-CT. On dynamic images, the MRI appearance of the pancreas is similar to that 
on contrast-enhanced CT, being hypointense to adjacent pancreatic parenchyma, but 
at times also appearing isointense, in which case identification of the primary tumour 
can be difficult. 149 Therefore its diagnostic sensitivity (84%) and specificity (82%) is 
significantly worse than CT.143 It was thought that MRI or magnetic resonance 
angiography (MRA) may improve resectability assessment in PDAC with better 
identification of vascular structures however a meta-analysis comparing MRA to CT 
found no significant difference in assessing preoperative vascular invasion.150 MRI 
may however be useful in the evaluation of pancreatic liver metastases thus avoiding 
unnecessary major operations without improved survival and reducing delay in 
starting chemotherapy. Certainly in colorectal cancer, MRI is better than CT at 
assessing liver metastases.151  
 
A meta-analysis of 1,582 patients152 found PET-CT was able to diagnose pancreatic 
cancer with a sensitivity of 0.91 (95%CI: 0.88-0.93) and specificity of 0.81 (95%CI: 
0.75-0.85). The sensitivity in detecting liver metastases was 0.67 (95%CI: 0.52-0.79), 
suggesting that the value of PET for this reason remains uncertain. However, PET-
CT may be useful in determining other extra-pancreatic sites of disease e.g. lung or 
bone metastases, when an indeterminate lesion is seen on CT. 
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In addition endoscopic retrograde cholangiopancreatography (ERCP) is useful in 
jaundiced patients to allow placement of an endoscopic stent to relieve obstruction 
and can be used to obtain ductal brushings and lavage, providing tissue for 
diagnosis114. 
 
Each patient with suspected pancreatic cancer must be discussed at a pancreatic 
multidisciplinary team (MDT) meeting involving pancreatic surgeons, 
gastroenterologists, radiologists, oncologists and nurse specialists. Investigations 
including blood tests, radiological imaging, FNA results and/or tissue biopsy results 
will be reviewed in order for a diagnosis of PDAC to be made, for staging of the 
disease and for management decisions.  
 
 
TNM Stage Description 
T-Stage  
             Tis Carcinoma in situ 
             T1 Tumour <2cm and limited to pancreas 
             T2 Tumour >2cm and limited to pancreas 
             T3 Tumour extends beyond pancreas but no involvement of 
coeliac axis or SMA 
             T4 Tumour involves the coeliac axis or SMA 
N-Stage  
             N0 Regional lymph nodes not involved 
             N1 Regional lymph nodes involved 
M-Stage   
             M0 No distant metastases 
             M1 Distant metastases present 
Table 1:  TNM staging of pancreatic cancer according to The American Joint Committee on Cancer (AJCC) TNM 
staging system.  T=tumour; N=nodes; M=metastases; SMA = superior mesenteric artery. 
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Clinical 
Stage 
Resectability TNM Stage Description Median Survival 
Stage I Resectable T1-2 N0 M0 Tumour limited to the pancreas, 
no extra pancreatic disease, no 
lymph node involvement 
17-23 months 
Stage II Resectable T3 N0 M0 or 
T1-3 N1 M0 
No involvement of SMA or 
coeliac axis, lymph nodes may 
be involved 
17-23 months 
Stage III Borderline 
resectable 
T4 N0-1 M0 Tumour abutment or <180° 
circumference of the SMA or 
coeliac axis 
Up to 20 months 
Stage III Unresectable T4 N0-1 M0 Tumour encasement >180° 
circumference of the SMA 
coeliac axis 
8-14 months 
Stage IV Metastatic T1-4 N0-1 M1 Metastatic disease 4-6 months 
Table 2:  Clinical staging of pancreatic cancer and survival.  T=tumour; N=nodes; M=metastases; SMA = superior 
mesenteric artery. Adapted from129 
 
1.7 BIOMARKERS 
 
A biological marker (biomarker), as defined by the National Institutes of Health 
Biomarker Working Group, is “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological process, pathogenic processes, or 
pharmacological responses to a therapeutic intervention.”  An ideal biomarker for 
pancreatic cancer would allow for early detection of disease in ‘at-risk’ patients or as 
part of a screening process, help to predict recurrence of disease following surgery 
and assess disease response to therapy.  It must have a high sensitivity and 
specificity, a good correlation with clinical stage and be an acceptable test to the 
target population with few complications.  In the clinical setting of pancreatic cancer, 
the most commonly used and validated biomarker is CA 19-9 as discussed above.  
However, due to its sensitivity and specificity, there is considerable interest in the 
scientific world to find a new biomarker for pancreatic cancer.  There are numerous 
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reports of a large number of potential biomarkers in the literature, including various 
microRNAs, DJ-1, cyclophilin B, IL-8, APRIL, MIC-1, PAM4, OPN, HSP27, TPS, TPA, 
POA, TSGF, CAM 17.1, REG-4, haptoglobin, MUCINS, M2-PK, to name but a few 153 
154.    They may be derived from serum, tissue, bile, pancreatic juice, saliva or stool, 
however, most lack large-scale validation.  Some have concentrated on gene 
expression in tissue and blood and on circulating tumour cells.  This thesis hopes to 
be able to add to the discussion by assessing biomarkers as predictors of early 
disease recurrence namely investigating circulating tumour cells, cell-free DNA and 
microRNAs. 
 
1.8.1 MANAGEMENT OF PANCREATIC CANCER 
 
As one of the most difficult cancers to treat, pancreatic cancer remains one of the 
most devastating solid tumours.  The tumour biology of PDAC renders the disease 
incredibly resistant to virtually all chemotherapy agents and the management is a 
worldwide challenge.  The only curative management option is surgical resection 
however only 15-25% of patients have a surgically resectable tumour at diagnosis.155   
This is due to a variety of factors including the retroperitoneal location of the 
pancreas and the late onset of symptoms, vague abdominal and systemic symptoms 
and the aggressive nature of the disease in terms of tumour proliferation, 
invasiveness and metastatic potential.  Features that preclude surgery in PDAC 
include distant metastatic disease and invasion of the tumour into local arteries, 
namely the coeliac axis or the superior mesenteric artery (SMA).  Local invasion of 
the tumour into the portal vein (PV) or superior mesenteric vein (SMV) is seen by 
many as a further contraindication to surgical resection.  However, more recently 
some specialist high volume pancreatic centres are performing PV/SMV resection 
routinely in patients with probable venous invasion.  57.1% of patients who have 
surgical resection of their pancreatic tumour have an R1 resection (tumour within 
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1mm of the resection margin)156 and a median survival of 17.2 months.  Even those 
with an R0 resection (no tumour within 1mm of the resection margin, a curative 
resection) only have a median survival of 28.7 months.156  Leading many to see 
PDAC as a ‘systemic’ disease at diagnosis and that resection is simply a ‘debulking’ 
procedure that is inadequate to cure microscopic and undetectable metastatic 
disease.  Nonetheless survival is much improved from the 8-14 months in those with 
unresectable locally advanced pancreatic cancer and 4-6 months in those presenting 
with metastatic disease.129 
 
1.8.2 SURGICAL MANAGEMENT  
 
With advances in radiological techniques, PDAC is being identified at an earlier stage 
and more patients are deemed suitable for surgical resection than previously.  The 
surgical management of PDAC depends on the location of the tumour.  Removal of 
the head of the pancreas (HOP), where 65% of tumours are located,128 involves a 
pancreaticoduodenectomy (PD): either a Whipples procedure or pylorus preserving 
pancreaticoduodenectomy (PPPD). Both operations are well described and these 
open procedures have become the gold-standard technique in pancreatic centres.  A 
distal pancreatectomy and splenectomy is performed when the tumour is in the body 
or tail of the pancreas.  Pancreatic resections can take several hours to perform 
requiring great surgical expertise so most countries have now centralised pancreatic 
surgery ensuring that only hepato-pancreato-biliary (HPB) surgeons undertake these 
operations in high volume centres.  As such, with improvements in surgical skill and 
post-operative care, the morbidity and mortality for these procedures is very 
acceptable. 
 
A PD involves the en-bloc removal of the distal stomach and pylorus (whipples only), 
the duodenum, the HOP, the common bile duct and the gallbladder.  A complete 
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oncological operation necessitates this resection due to the anatomical proximity of 
these organs and shared blood supply of the HOP and proximal duodenum (the 
gastroduodenal artery).  Three anastomoses are required at PD:  Firstly, a 
pancreaticoenterostomy, either as a pancreaticogastrostomy or 
pancreaticojejunostomy, in order to re-connect the remaining pancreas and main 
pancreatic duct to the gastrointestinal (GI) tract; a gastrojejunostomy, to re-connect 
the stomach to the jejunum in a whipples procedure or a duodenojejunostomy, to re-
connect the post pylorus duodenum to the jejunum in a PPPD; and a 
hepaticojejunostomy (choledochojejunostomy) to re-connect the common hepatic 
duct to the GI tract (Figure 2).  A roux-en-Y loop is created in order to prevent gastric 
biliary reflux with resultant gastritis and oesophagitis.  Surgeons will differ on the 
technique for each of these anastomoses.157  Advantages of the PPPD compared to 
whipples may include reduced experience of dumping syndrome, reduced blood loss 
and shorter operating times. PPPD may be associated with a higher incidence of 
delayed gastric emptying and have poorer oncological outcomes.158  However, no 
differences in terms of morbidity, mortality or survival were found in a recent 
Cochrane review.159 
 
Recent large observational studies evaluating PD for PDAC have been encouraging.  
Winter et al. looked at 1423 patients who had PD and found a median blood loss of 
800mls and median length of operation of 380mins.160  Morbidity was 38% and 
perioperative mortality only 2%.  Indeed, others have shown similar morbidities of 
20%-47.2%, with improvements when patients are on an enhanced recovery 
programme.161  The most common complications are delayed gastric emptying 
(DGE) (20-50%162), post-operative pancreatic fistulas (POPF) (10-15%162) and wound 
infections (11%163).  Others include post-operative bleeding (4-16%162), anastamotic 
leaks including biliary fistulas (1-5%162) and intestinal fistulas (3-8%162), pancreatitis 
(2-3%162), and ischaemic complications (1%162).  DGE is defined as the impossibility 
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of resuming oral feeding after the first postoperative week or prolonged use of a 
nasogastric aspiration tube.164 and is graded from A to C according to its clinical 
impact and management.  It can severely alter the nutritional state of a patient, 
prolonging hospital stay and has been known to last for up to 6 weeks.165  It may be 
due to:  Damage to the gastric vagus nerve system; a decrease in the plasma 
concentration of gastric motilin due to peripancreatic inflammation; the angulation or 
twisting of the gastrojejunostomy; and/or secondary to dissection of peri-pancreatic 
lymph nodes.162  A POPF is defined as any volume of drain fluid after postoperative 
day 3, with amylase content greater than 3 times serum.166 They are further classified 
by grade according to clinical severity. Grade A fistulas are considered “transient 
fistulas” and have no clinical impact.  Grade B fistulas require parenteral nutrition, 
antibiotics, or somatostatin analogues and may require re-positioning of drains. 
Grade C fistulas require a major change in clinical management, such as surgical 
exploration and often lead to an extended hospital stay. 
 
Many are now also performing these operations laparoscopically further improving 
post-operative recovery for the patient.  Laparoscopic pancreaticoduodenectomy 
(LPD) was first described by Gagner and Pomp in 1994167. Technically LPD is quite a 
demanding operation.  As such, historical opposition of LPD has focused on 
concerns such as the difficulty in accessing and adequately exposing the pancreas, 
the lack of ability to control haemorrhage from major vessels and the feasibility of 
performing sophisticated anatomical reconstructions and anastomoses with 
laparoscopic instruments. These worries have been voiced in concert with 
suggestions that LPD may compromise patient outcomes, by the inability to maintain 
oncologic surgical principles due to surgeon fatigue secondary to prolonged 
operative times and by the inability to palpate the tumour itself and/or surrounding 
vasculature.168  Some concerns about the technical demands of PD laparoscopically 
persist because there is a lack of Level I evidence to categorically prove the safety 
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and benefits of LPD for these patients. To date there have been no randomised 
controlled trials of laparoscopic versus open PD reported in the literature. Available 
evidence ranges from case reports to non-randomised comparative studies with 
relatively small numbers, which generally fail to reach statistical significance for the 
majority of findings. Many of the LPD series reported in the literature exclude patients 
with significant co-morbidities or those likely to have difficult PDs, such as those with 
large tumours, vascular involvement, non-dilated ducts and extension of tumour to 
the uncinate process.168 Furthermore, patient preference for laparoscopic or open PD 
introduces selection bias to potentially confound the reliability of these findings.169 170 
Interpretation of the literature on LPD is made more difficult by the wide variety of 
technical practices at different centres.  For instance some report an entirely 
laparoscopic completion of LPD, whilst others may perform the anastomoses through 
a small midline incision.170 171  Despite reservations about the quality of data available, 
a meta-analysis of LPD published in 2011 is cause for optimism. Of the 126 patients 
included in the review, none had positive tumour resection margins.168 Subsequently, 
it has been found that in spite of longer operations, mean estimated blood loss, 
number of units of RBCs transfused peri-operatively, length of post-operative ICU 
stay and length of overall hospital stay are better after LPD than open PD (OPD), 
with comparable morbidity and mortality. 169 There is also no significant difference in 
tumour size, TN stage, number of positive lymph-nodes or R0 resections between 
either group.169 A lower positive lymph-node to negative lymph-node ratio and a 
significantly higher total number of lymph-nodes harvested is also seen after LPD, a 
positive predictor of better long-term survival 171.  As alluded to above, a small 
number of centres have reported their experience of robotic LPD, with some 
promising early results. Studies have detected an increase in R0 resections,172 173 
with one study quoting an increase from 58% to 87% with the introduction of robotic 
PD. 173 Similar to LPD, robotic LPD has been reported to increase the number of 
lymph-nodes harvested and reduce operative blood loss when compared to open 
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operations.172 173 Interestingly, robotic LPD may actually have shorter operative times 
than OPD.174 Any consideration of the prospective benefits of robotic LPD should, 
however, take into account the fact that the costs of the robotic operation are 
estimated at more than twice that of the non-robotic LPD and appreciably more 
expensive than OPD.175 170  A randomised controlled trial comparing LPD with OPD is 
clearly required to assess surgical and oncologic parameters. Although the number 
of centres offering LPD and the number of patients suitable for LPD are both 
increasing, the institution of a sufficiently powered RCT comparing LPD to OPD 
poses sizeable logistical issues. However, the literature to date, demonstrates that 
LPD is feasible, safe and very promising in selected patients.  
 
Distal pancreatectomy (DP) is performed with splenectomy for a complete 
oncological operation.  There has been a marked improvement in outcomes following 
this operation in recent years and it is routinely performed both as an open and 
laparoscopic procedure in high volume HPB centres.  The main complication 
following DP is POPF.  POPF rates vary in the literature from 6%-32%.176  Other 
complications relate to those of pancreatic insufficiency with endocrine failure seen in 
23·4% and exocrine failure seen in 15.6%.177  This operation also carries a risk of 
sepsis, meningitis or pneumonia, triggered mainly by S. pneumoniae, N. meningitidis 
and H. influenza, which is 35 times higher in patients following splenectomy than in 
the general population.178  Following splenectomy, the incidence of infection is 3.2%, 
with a mortality of 1.4%.179  There is no difference in morbidity and mortality between 
open and laparoscopic DP.176  Five-year survival after DP for PDAC is similar to 
patients having surgery for HOP PDAC.158  More recent techniques for DP including 
the radical antegrade modular pancreatosplenectomy (RAMPS) procedure, maximise 
the chance of negative resection margins, with 81% achieving R0 resections.180  In 
addition, a radical distal pancreatectomy with resection of the coeliac axis (DP-CAR), 
is carried out by some surgeons for pancreatic body tumours, with excellent R0 
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resection rates of up to 91% although with a 48%-54% morbidity181, 182  Median 
survival has been reported as 21 months by some182 but as poor as 9.25 months by 
others.181  Recently, a scoring system has been developed to predict prognosis in 
DP-CAR patients that may allow for greater selectivity.183 
 
 
 
Figure 2: Pancreaticoduodenectomy. (A) The tissue to be resected in a standard pancreaticoduodenectomy. (B) 
Reconstruction after a standard pancreaticoduodenectomy. (C) Reconstruction after a pylorus-preserving variation. 
From158  
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1.8.3 SURGICAL MANAGEMENT TO REDUCE RECURRENCE RATES 
 
In an effort to reduce the risk of post-operative disease recurrence and improve 
survival there have been a number of techniques described in the literature for 
pancreaticoduodenectomies including:  The no-touch technique; portal vein 
resection; arterial resection; and newer techniques including radiofrequency ablation 
(RFA) and irreversible electroporation therapy (IRE) 
 
The no-touch technique:  In 1967 Turnbull reported a no-touch technique in the 
operative management of colon cancer.184  He adopted a technique deliberately 
avoiding any tumour manipulation until lymphovascular ligation was complete. Using 
this technique on 460 patients with colorectal cancer compared to standard 
colectomy on 120 patients, the five-year survival improved from 34 to 50 months. It 
was postulated that limiting the handling of the tumour prevents the spread of cancer 
cells. Subsequently, it was noted that using this technique for colorectal cancer, liver 
metastases appeared later, and in fewer patients 185.  
 
More recently, Kobayashi et al. applied the no-touch technique to PD in 10 patients 
with periampullary tumours186.  Briefly, the no-touch technique mandates that the 
tumour in the head of the pancreas must not be touched until complete ligation and 
division of the venous drainage. In the original Kobayashi paper there was no 
operative mortality and none of the patients developed liver metastases after a 
follow-up of between 5 months – 7 years. Further corroboration of the no-touch PD 
came from Hirota et al. who used this technique on 8 patients with pancreatic cancer 
and compared it to the conventional technique used with 10 patients.187  The authors 
measured portal vein (PV) carcinoembryonic antigen (CEA) messenger RNA before 
and after tumour manipulation. No patients had detectable levels before resection but 
PV CEA messenger RNA was detected in only 13% (1/8) of those undergoing the no-
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touch technique compared to 50% (5/10) of patients having the standard PD. 
Patients in the no-touch group had a significantly lower recurrence rate (38% 
compared to 90%; p=0.043) and longer overall survival (41.5±5.6; 95% CI: 30.5-52.5) 
months compared to 21.2±5.8 (95% CI: 9.9-32.5; p=0.018) months. The authors later 
published a report showing a 40% morbidity rate and no operative mortality using this 
technique for PD in 42 patients188. For the 17 patients with PDAC, 14 (82%) had R0 
resection margins and 3 (18%) had R1 resections.  The two-year survival was 75%.  
These results are comparable to findings reported with the conventional technique 
and it is thus a feasible and safe operation.  It is possible that handling the tumour at 
the time of standard surgery causes a release of circulating tumour cells (CTCs), 
hence contributing to future disease recurrence, an occurrence, which may therefore 
be improved without tumour manipulation during the no-touch technique.    
 
There is limited data on the no-touch technique with small numbers of patients in 
each group. However, the technique is possible for PD, does not increase morbidity 
or mortality, and appears to have the possibility of improving oncological outcomes in 
PDAC patients who undergo PD.  This thesis aims to investigate the no-touch 
technique and its impact on disease recurrence by using available biomarkers. 
 
Portal vein resection:  A previous contraindication to PD was local invasion of the 
tumour into the portal vein (PV) or superior mesenteric vein (SMV). However, more 
recently some specialist high volume pancreatic centres are performing PV/SMV 
resection routinely in patients with probable venous invasion. This element of PD 
remains somewhat controversial as it adds considerably to the complexity of the 
operation thereby increasing the possibility of bleeding, portal vein thrombosis, 
morbidity and mortality for the patient without conferring major improvement in long-
term survival. There are currently no RCTs analysing the safety of performing 
PV/SMV resection in patients with PDAC. Nonetheless, from observational studies, 
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operative morbidity and mortality have been consistently reported as not significantly 
different between PD with versus without PV/SMV resection 189 190 191 192 193 194 195 196. 
Furthermore, the potential benefit of PV/SMV resection was evaluated in a recent 
systematic review of 1,458 patients from 28 level III evidence studies.197 Median 
survival was 15 months (9-23 months) and the authors concluded that in high-volume 
centres, vascular resection has acceptable morbidity, mortality and survival 
outcomes and should not be seen as a contraindication to curative surgery. By 
pooling results from studies reporting resection margin status after PD,156, 198-204 a 
positive medial resection margin was reported in 38.2% of 701 patients. However, 
following PD with PV/SMV resection, the medial resection margin is only positive in 
16% of patients and it is well recognised that an R0 medial resection margin is a 
predictor of improved survival.156, 199 200-204 
Of further considerable interest was a recently published paper by a group in 
Marseille 205 who performed PV/SMV resection with curative intent on 34 patients 
with pancreatic adenocarcinoma. Histopathological examination found that 19 
patients had no tumour invasion of the resected vein. These were compared to 
patient and tumour-matched controls i.e. patients who had PD without PV/SMV 
resection, all with negative resection margins. Of note median survival was 42 
months in the PV/SMV resection group compared to 22 months (p=0.02). The 
group’s finding inevitably now generates the question as to whether the PV/SMV 
resection should be performed routinely in PD even when there is no suspected 
venous tumour infiltration. 
 
Arterial resection:  Performing PD with arterial resection is more controversial.  
Although arterial invasion is seen as a contraindication to surgery, there is now some 
observational data suggesting that this operation is feasible in those with locally 
advanced disease and may be associated with more favourable survival compared 
with patients who did not undergo resection.206  However, a PD with arterial resection 
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carries an appreciable peri-operative mortality and increased morbidity thus cases 
must be highly selected.   
 
Newer Techniques:  There are some newer ‘cutting-edge’ techniques, which have 
been developed and may have a part to play in pancreatic cancer surgery. 
Radiofrequency ablation (RFA), or microwave ablation, has been successfully used 
in the treatment of solid tumours in the liver, lung, breast, kidney and many other 
tumour types. This technique has also been demonstrated to be safe and promising 
when performed percutaneously or endoscopically for locally advanced PDAC 207, 208 
209 210. Increasingly, there is evidence from series around the world that open intra-
operative RFA is a feasible way to provide tumour cytoreduction and partial necrosis 
in locally advanced pancreatic tumours, leading to good survival rates and an 
improvement in quality-of-life 211 209.  However, some have shown an increased risk 
of pancreatic fistula, duodenum perforation and abscess formation, and mortality 
related to the intervention without a clear evidence of survival benefit.  Another 
exciting emerging modality for treatment of PDAC is Irreversible Electroporation 
therapy (IRE), or NanoKnife® technology. IRE is an ablation technology, which unlike 
RFA is not based on thermal damage to tissue, and has shown to be safe near 
vascular and ductal structures. IRE uses focused electrical energy to create 
nanoscale pores within the cell membranes of precisely targeted tissues to destroy 
cells within a narrow range whilst leaving neighbouring cells unaffected. The potential 
for use in PDAC where the tumour is adjacent or involved in key local vascular 
structures is clear. To date, IRE has been demonstrated to be feasible, and of value 
to patients as an intra-operative adjunct for open curative PD tumour margin 
accentuation, and in open intra-operative tumour palliative ablation 212 213.  However, 
application of this may promote tumour spread and disturbance.  It remains to be 
seen if there is any benefit at all to patients with locally advanced pancreatic cancer.   
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1.8.4 ONCOLOGICAL MANAGEMENT 
 
Adjuvant Therapy:  In line with the view that pancreatic cancer is a ‘systemic’ disease 
is the opinion that all patients who have undergone resection of PDAC should be 
given the option of adjuvant therapy. The European Society for Medical Oncology 
(ESMO) and the National Comprehensive Cancer Network (NCCN) both advocate 
the use of adjuvant therapy, even in those with resected T1N0 disease214.  High rates 
of both distant and local recurrence have spurred cure efforts with systemic 
chemotherapy, radiotherapy and combination chemoradiotherapy. The survival 
benefit of adjuvant chemotherapy is clear, but the benefit of radiotherapy remains 
disputed. The optimal adjuvant treatment modality is thus yet to be defined.  Adjuvant 
chemotherapy is usually initiated within four to six weeks of surgery and continued for 
a total of six months, however, optimal timing and duration has not been specifically 
addressed by randomized controlled trials. 
 
 A regimen of adjuvant chemotherapy is supported by 1A level evidence 215, and 
chemotherapy alone is the therapeutic strategy most commonly practiced in the UK. 
Choice of chemotherapeutic agents is primarily between fluoropyrimidine-based 
regimens and gemcitabine216, 217. Gemcitabine is usually the preferred agent given its 
greater tolerability in regimens involving a monthly bolus 218. However, some 
clinicians argue that a weekly or infusional fluoropyrimidine schedule has an equally 
tolerable side effect profile and similar efficacy. Nevertheless, gemcitabine 
1000mg/m2 weekly for 3 weeks followed by 1 week of rest is the most commonly 
used regimen.  
 
The rationale for chemoradiotherapy in addition to adjuvant chemotherapy is to 
prevent local recurrence in the pancreatic bed. 15% of patients who have surgery 
alone for stage I or II disease have local recurrence alone whilst 65% have both 
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locally recurrent and metastatic disease 219. There is level 2B evidence supporting 
combined modality therapy, with infusional 5-fluorouracil regimens favoured over 
gemcitabine or bolus FU during the concurrent chemoradiotherapy portion220-223. 
Alternatively, capcetabine can be substituted for infusional FU therapy as a radiation 
sensitizer in patients with locally advanced pancreatic cancer as has been shown in 
trials for other gastrointestinal malignancies224-226. The regimen may consist of 
gemcitabine 1000mg/m2  weekly for 3 weeks, with concurrent chemoradiation starting 
1-2 weeks after gemcitabine. Chemoradiation would consist of 5-fluorouracil 
continuous IV infusion via pump during radiation and radiotherapy of 1.8Gy/day for a 
total of 50.4 Gy.  A further 3 cycles of gemcitabine would take place 3-5 weeks after 
chemoradiation.    
 
Relevant trials: 
CONKO-001 trial 217– Multinational trial in which 368 patients were randomly 
assigned to gemcitabine or no treatment after surgery. A 5-year survival benefit of 
21% versus 10% was shown.  
ESPAC-3 trial 218– Multicentre trial in which 1088 patients were randomly assigned to 
six months of gemcitabine or luecovorin-modulated FU after surgery. After a median 
follow-up of 34 months, median survival was similar (23.6 versus 23 months 
respectively), but patients assigned to FU/leucovorin had more grade 3 to 4 
treatment-related toxicity.  
 
Treatment in unresectable cases:  Therapeutic options for patients with unresectable 
PDAC include chemotherapy alone, chemoradiotherapy or radiotherapy alone. 
Specific methods for symptom palliation also have a significant role to provide relief 
of pain, obstructive jaundice, gastric outlet obstruction, and pancreatic exocrine 
insufficiency. 
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Systemic chemotherapy for patients with advanced pancreatic cancer has been 
shown to improve disease-related symptoms and survival compared to supportive 
treatment alone. FOFIRINOX, a combination chemotherapy regimen consisting of 
oxaliplatin, irinotecan, fluorouracil, and leucovorin, has been shown to be superior to 
gemcitabine in objective response rate (39% versus 11%) for patients who have a 
very high performance status and who can tolerate an intensive approach 227. For 
those who cannot tolerate this regimen, a less toxic alternative combining 
gemcitabine with paclitaxel or capecitabine may be trialed 228-230. Meanwhile, 
gemcitabine monotherapy provides the mainstay of treatment for the majority of 
patients, who cannot tolerate the side-effect profile of the above more intensive 
regimens and is associated with significant clinical benefit 231, 232.  
 
For patients who fail gemcitabine monotherapy or FOLFIRINOX therapy but maintain 
good performance status, second-line therapy should be considered. This may 
involve a oxaliplatin/fluoropyrimidine combination such as FOLFOX following 
gemcitabine monotherapy 233, 234, or gemcitabine monotherapy itself following 
FOLFIRINOX therapy 235.  
 
Patients with locally-advanced, unresectable cancer may also benefit from 
chemoradiotherapy provided they have not developed metastases during the initial 
phase of chemotherapy.  Chemoradiotherapy with external beam RT plus 
concomitant low-dose infusion FU or capecitabine should be considered. The 
hypothesis for chemoradiotherapy’s efficacy in this cohort of patients is that a period 
of initial disease control with chemotherapy can select patients without occult 
micrometastatic disease who might benefit from radiotherapy 236-238.  
 
Relevant trials:   
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Burris trial 232– 126 patients with advanced symptomatic cancer were randomized to 
receive either gemcitabine or fluorouracil, A better clinical benefit response (24% 
versus 5%), improved median overall survival (5.6 months versus 4.4 months) and 
improved 1-year survival (18% versus 2%) were observed.  
ACCORD 11 trial 227– 250 patients with chemotherapy-naïve, metastatic pancreatic 
cancer with an excellent performance status were randomly assigned to gemcitabine 
alone versus FOLFIRINOX. Patients treated with FOLFIRINOX showed significantly 
higher objective response rate (32% vs 9%) as well as median progression-free 
survival (6.4 vs 3.3 months) and overall survival (11.1 vs 6.8 months).  
 
Neoadjuvant therapy in borderline resectable cases:  Borderline resectable cases 
may represent patients who have focal tumour abutment of the visceral arteries or 
involvement of the superior mesenteric vein or portal vein that is potentially 
resectable and reconstructable. Operations on such cases are unlikely to achieve 
complete resection, thus spurring efforts to ‘downstage’ the tumour pre-operatively 
using chemotherapy with or without radiotherapy. This neoadjuvant therapy is highly 
controversial and has a poor evidence base, but the theory is that it may increase 
rates of margin-negative resections, provide early treatment of micrometastatic 
disease as well as to improve selection for patients for whom resection will not offer a 
survival benefit.  
 
One proposed treatment algorithm for borderline resectable cases involves use of 
chemotherapy with FOLFIRINOX (or gemcitabine with or without a combination 
agent), followed by re-evaluation after 2 and 4 months 239. If no distant metastases 
have occurred, radiotherapy may take place at this point and if at 6 weeks post-
treatment there is retained good performance status and no distant metastases, 
surgical exploration should take place. Some institutions would argue that if there is a 
good response to the initial neoadjuvant chemotherapy, patients should be taken 
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directly to surgical exploration without undergoing further radiotherapy. Given the 
lack of evidence for this algorithm, and that the best form of induction therapy to use 
is unclear, patients with borderline resectable disease should ideally be enrolled in 
clinical trials to further define any benefit of neoadjuvant therapy.  
 
Recent/novel trials:  There is increasing interest in molecularly-targeted therapies 
based on the biologic properties of pancreatic cancer. One such target is epidermal 
growth factor, which is frequently over-expressed in PDAC 240. A tyrosine kinase 
inhibitor of the receptor often used in lung cancer, erlotinib, has been shown to have 
a modest survival gain when compared to gemcitabine alone (1-year survival 23 vs 
17%) 241, however, this is unlikely to prove cost-effective. Other approaches have 
targeted angiogenesis and increased expression of vascular endothelial growth 
factor and its receptor 242. Disappointingly, despite promising phase II data, a phase 
III trial adding bevacizumab to gemcitabine in 602 patients did not reveal any benefit 
243, 244.  
 
Another attractive target has been the Ras oncogene and its encoded proteins - Ras 
mutations leading to constitutive activation are found in around 90% of pancreatic 
cancers 244, 245. Early studies targeting the Ras gene using vaccines and antisense 
molecules have shown promise 245. A further therapeutic strategy has been inhibiting 
the post-translational addition of farnesyl group to the Ras proteins. Benzodiazepine 
peptidomimetic analogues blocking this process restores a normal growth pattern in 
Ras-transformed cells in preclinical studies 246, but unfortunately phase III trials of 
farnesyltransferase inhibitors have shown lack of clinical benefit 247.  
  
 
 
 
 59 
1.9 AIMS AND OBJECTIVES 
 
The hypothesis of this thesis is that currently available biomarkers for pancreatic 
cancer would have little impact on predicting outcomes following intervention.  
 
At the time of starting this project there was little published research investigating 
differences between those with early disease recurrence following surgery for PDAC 
and those with no disease recurrence and whether surgical technique can alter 
recurrence rates.  Therefore our aims were: 
 
1) To review the literature regarding potential blood biomarkers in pancreatic cancer, 
namely cell-free DNA, circulating tumour cells and circulating microRNAs. 
2) To determine whether the no-touch technique for pancreaticoduodenectomy (PD) 
reduces the number of circulating tumour cells and improves the recurrence rate in 
PDAC patients compared to the standard PD technique. 
3) To identify clinicopathological factors that are significantly different between 
patients who develop disease recurrence within 12 months of pancreatic resection for 
PDAC and patients who do not develop disease recurrence for at least 2 years after 
surgery.  
4) To investigate genetic and epigenetic factors, that are significantly different 
between patients who develop disease recurrence within 12 months of pancreatic 
resection for PDAC and patients who do not develop disease recurrence for at least 
2 years.  
 To examine DNA changes in tumour tissue for each group. 
 To establish whether these DNA mutations can be identified in the 
peripheral circulation as cell-free DNA 
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 To determine the number of circulating tumour cells in these patients 
and establish whether any differences exist between each group 
 To examine microRNA expression in the peripheral circulation and 
establish whether any differences exist between each group 
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CHAPTER 2:   
Methods 
 
2.1 A Literature review of potential biomarkers in pancreatic cancer: 
 
A literature search for relevant studies using the search terms ‘biomarkers’ OR ‘liquid 
biopsy’ AND ‘Cancer’ OR ‘PDAC’ OR ‘pancreatic cancer’ OR ‘pancreatic neoplasm’ 
was conducted on PubMed, Embase, Web of Science, Cochrane Library and Google 
Scholar databases. The abstracts of these studies were scrutinised.  Publications 
were categorized and further searches were conducted on the categories with the 
most research published including: circulating tumour cells (CTCs), cell-free DNA 
and micro RNAs 
 
2.2 Surgical technique to reduce recurrence rates using CTCs as a biomarker: 
 
2.2.1 Ethics: Approval was obtained from a UK national research ethics committee 
(London; 08/H0706/35) and Imperial College Healthcare NHS Trust. 
2.2.2 Patients:  Patients undergoing PD for likely PDAC were identified. The main 
inclusion criteria were those patients undergoing curative resection for PDAC and 
who consented for intra-operative blood sampling.  A prior decision for tumour 
resection was made at the hepato-pancreato-biliary MDT meeting.  Patients were 
randomised into 2 groups: Standard pancreaticoduodenectomy, ST-PD (group I) and 
the no-touch technique pancreaticoduodenectomy, NT-PD (group II).  The primary 
endpoint was the increase in number of CTCs following resection.  Secondary 
endpoints were disease-free survival and overall survival. 
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2.2.3 Operative technique:  All operative procedures were performed by a single 
surgeon (LRJ). Our method for ST-PD has been previously detailed.248  In brief, with 
an assistant or the primary surgeon himself lifting and touching duodenum and the 
head of pancreas (HOP), the duodenum is first Kocherized to the posterior surface of 
pancreas at the level of left renal vein and inferior vena cava. Dissection of the liver 
hilum and ligation of gastroduodenal artery (GDA) is then performed close to its 
origin from the hepatic artery. Following tunnelling the pancreas above the superior 
mesenteric vein (SMV) and portal vein (PV) and division of jejunum, the surgeon 
places the left hand behind the HOP by holding the duodenum and head of pancreas 
to complete transection behind the pancreas.  In comparison, the concept of the NT-
PD is that the tumour must not be manipulated before the vascular and lymphatic 
drainage vessels are completely isolated and was performed as previously 
described.188  Following dissection of the liver hilum to identify the common bile duct 
(CBD) and PV, the CBD is divided below the junction of hepatic ducts and the GDA is 
ligated and divided. Next, the lesser sac is entered by dividing the gastrocolic 
ligament with the LigaSure Vessel Sealing System (Valleylab, Boulder, CO). After 
division of jejunum 5-10cm from the duodenal-jejunal (DJ) flexure with a 45mm 
stapler, the pancreas is tunnelled at the superior mesenteric vein (SMV) and portal 
vein (PV) and divided with a surgical scalpel. Superior, middle and inferior pancreatic 
veins are identified, ligated and divided. The SMV and PV are freed completely from 
pancreas. All lymphatic drainage to the portal hilus is divided. Finally, Kocherization 
was performed and the crural tissue between the uncinate process of pancreas and 
superior mesenteric artery (SMA) is divided by LigaSure to complete the PD. At all 
times during the procedure the HOP is not grasped by the surgeon and transection of 
pancreatic crural is performed only after ligation and division of the venous drainage. 
 
2.2.4 Blood sampling and analysis:  Following identification and exposure of the 
portal vein (PV), 7.5 mL of blood was drawn directly using a 21-gauge butterfly 
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needle before dissection and immediately after removal of the PD specimen. Blood 
samples were taken at each point in a CellSave (Veridex, NJ, USA) preservative tube. 
The samples were then processed in our laboratory within 24 hours using the bead-
based fluorescence CellSearch system (Veridex, NJ, USA) according to the 
manufacturer’s protocol. Samples were then scanned on the CellTracks analyzer II 
fluorescent microscope (Veridex, NJ, USA) for analysis. The cells were evaluated for 
CTCs independently by 2 operators (Figure 3).  
 
 
 
Figure 3: Identification of pancreatic circulating tumor cells (CTCs) in the portal venous circulation. (A) Shows a true 
CTC that is positive for EpCAM, pan-CK and DAPI, but negative for CD45; whereas (B) shows a leukocyte that is 
positive for CD45.  
 
2.2.5 Follow-up:  All patients had routine follow-up in the outpatients clinic at 3 
monthly intervals for the first year and then six monthly intervals.  Clinical 
examination, routine laboratory tests and a CT scan was organised at each 
appointment.  Contrast microbubble ultrasound scan, positron emission tomography 
(PET) or bone scintigraphy was arranged to detect distant recurrence as necessary.  
Disease recurrence and date of death was determined from death certificates, clinic 
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letters and radiological findings.  Date of disease recurrence was recorded as the 
date of the first CT scan to diagnose abnormal pathology.  Follow-up continued until 
date of death or until July 2014 for surviving patients.  Disease-free and overall 
survival was defined as the interval between date of surgery and date of death or 
final follow-up. 
2.2.6 Statistical Analysis:  The statistical analyses were performed using IBM SPSS 
statistics version 21 software package (IBM SPSS, Chicago, USA).  Univariate 
analysis comparisons were made using Fisher’s exact test for categorical data and 
the Wilcoxon signed rank test for continuous data.  All tests were two-sided. Disease-
free and overall survival rates were calculated by Kaplan-Meier method and 
compared by the log-rank test.  A p-value <0.05 was considered significant. 
2.2.7 Power calculation:  We estimated that 85% of patients would have an increase 
in number of CTCs following the standard pancreaticoduodenectomy.  We would 
consider it clinically significant if only 20% of patients had an increase in CTC 
numbers following the no-touch technique.  We estimated that the sample size 
required to detect this difference at 90% power and 5% level of confidence to be 6 in 
each group using the following formula.  Where π1 is 85% and π2 is 20% 
N in each group = f(α, β) x ((π1 x (100 – π1) + π2 x (100 – π2))/ (π1-π2)2) 
 
2.3 Clinicopathological factors which may predict disease recurrence: 
2.3.1 Ethics: This study was approved by our institutional review board 
(Hammersmith Hospital, Imperial Healthcare NHS Trust).  Informed written patient 
consent for research was obtained before surgical treatment. 
2.3.2 Patients:  All patients who had a pancreatic resection from January 2001 to 
June 2014 were included in our retrospectively created database.  Inclusion factors 
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for this study were: patients with histopathologically confirmed pancreatic ductal 
adenocarcinoma (PDAC) who had a pancreatic resection during this time period 
including pancreaticoduodenectomy (PD) and distal pancreatectomy (DP); and 
patients who developed disease recurrence (either local or distant disease) within 12 
months from the operative date or who had no disease recurrence for at least 24 
months after surgery.  Exclusion factors included: Patients with alternative diagnoses 
either benign disease or malignant including ampullary carcinoma, 
cholangiocarcinoma, duodenal carcinoma, cystadenocarcinoma or neuroendocrine 
tumours; patients under 18yrs of age; patients with abandoned resections (due to 
locally advanced disease or metastases seen intra-operatively) or R2 resections.  
After preoperative evaluation with a triple phase pancreas protocol computed 
tomography (CT) scan and/or endoscopic ultrasound (EUS) +/- fine needle aspiration 
(FNA) and/or magnetic resonance imaging (MRI), a decision for surgery was made at 
our hepatobiliary multidisciplinary team (MDT) meeting.  Surgery is offered to those 
who fit the criteria for pancreatic resection:  absence of extrapancreatic disease; no 
involvement of the superior mesenteric artery (SMA) or coeliac axis; no encasement 
of the superior mesenteric vein (SMV) or portal vein (PV) >180°; and fit to undergo 
major surgery (WHO performance status of 0-2).  For patients with local venous 
invasion with <180° encasement, resection and reconstruction of the SMV or PV is 
performed as required.  Preoperative data included age, sex, past medical history 
and bloods including CA 19-9, bilirubin and CRP.  The cut-off value used for CA 19-9, 
bilirubin and CRP was 37 kunits/L, 22 umol/L and 20 mg/L respectively, in 
accordance with the literature.249, 250 
2.3.3 Operative procedures: All operations in our unit are performed by consultant 
hepatopancreatobiliary surgeons and have been previously described.248  Both 
whipples procedure and pylorus preserving pancreaticoduodenectomy (PPPD) are 
routinely performed as standard, without extended lymphadenectomy,  Retroportal 
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resection extends to the tissues in the groove between the uncinate process and 
SMA.  The pancreatico-enteric anastamosis is decided during the procedure by the 
surgeon and performed as either a pancreaticojejunostomy or 
pancreaticogastrostomy.  PD is performed laparoscopically where possible.  
Tangenital or segmental resection of the SMV or PV is performed when the 
pancreatic head or uncinate process can’t be separated from the vein without leaving 
macroscopic tumour or risking venotomy.  Transection margins are analysed with 
frozen section intraoperatively and further resection undertaken until negative 
margins obtained histopathologically.  DP and splenectomy is performed 
laparoscopically where possible by standard techniques.  An abdominal drain is 
placed during the procedure and kept until output is <30mls in 24 hours. 
2.3.4 Histopathological examination:  The gross and microscopic examination of 
specimens is performed by a hepatopancreatobiliary histopathologist according to 
the guidelines of the Royal College of Pathologists (available at 
http://www.rcpath.org).  These guidelines recommend that the status of six discrete 
resection margins be documented by the reporting pathologist: the pancreatic 
transection margin, the medial (or superior mesenteric vessel) margin, the posterior 
margin, the proximal duodenal (or gastric) margin, the distal duodenal margin and the 
common bile duct margin. Microscopic evidence of tumour involvement within 1mm 
of any one of these six margins results in an R1 classification.201  The pancreatic 
head is sliced at 5 mm intervals producing 10–13 slices. These slices are embedded 
whole in megablocks allowing extensive views of the lesion and its relation to the 
entire CRM and key anatomical structures.204  Tumour size, tumour differentiation, 
total number and number of involved lymph nodes, resection margin status, the 
presence of perineural and/or lymphovascular invasion is recorded.  The lymph node 
ratio is the number of lymph nodes involved to the total number of lymph nodes and 
the cut-off used was 0.2, in accordance with the literature.251 
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2.3.5 Follow-up:  All patients had routine follow-up in the outpatient clinic at 3 monthly 
intervals for the first year and then six monthly intervals.  Clinical examination, routine 
laboratory tests and a CT scan was organised at each appointment.  Contrast 
microbubble ultrasound scan, positron emission tomography (PET) or bone 
scintigraphy was arranged to detect distant recurrence as necessary.  Disease 
recurrence and date of death was determined from radiological findings, clinic letters, 
and death certificates.  Date of disease recurrence was recorded as the date of the 
first CT scan to diagnose abnormal pathology.  Follow-up continued until date of 
death or until July 2014 for surviving patients.  Disease-free and overall survival was 
defined as the interval between date of surgery and date of death or final follow-up. 
2.3.6 Statistical Analysis:  The statistical analyses were performed using IBM SPSS 
statistics version 21 software package (IBM SPSS, Chicago, USA).  The two groups 
consisted of those with disease recurrence within 12 months and those with no 
recurrence for at least 24 months.  Univariate analysis comparisons were made using 
Fisher’s exact test for categorical data and the Wilcoxon signed rank test for 
continuous data.  All tests were two-sided.  Variables that were significantly different 
(p<0.1) were included in a cox regression analysis to examine the impact of these 
variables on early disease recurrence. Overall survival rates were calculated by 
Kaplan-Meier method and compared by the log-rank test.  
 
2.4 Are disease recurrence rates affected by genetic and epigenetic changes and 
can these be detected in the peripheral circulation?: 
 
2.4.1 Ethics: Approval was obtained from a UK national research ethics committee 
(London; 09/H0722/77) and Imperial College Healthcare NHS Trust. 
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2.4.2 Patients:  All patients with pancreatic ductal adenocarcinoma who underwent a 
pancreatic resection from January 2001 until June 2014 were included on a 
retrospectively collected database.  From this database, those who developed 
disease recurrence within 12 months from the date of the operation (Group I) and 
those that did not develop disease recurrence for at least 24 months (Group II) were 
identified. 
 
2.4.3 Tumour samples:  The formalin-fixed paraffin-embedded (FFPE) blocks and 
corresponding H&E stained slides for these patients were collected.  These were 
reviewed with a specialist pancreatic pathologist. Areas of PDAC were then marked 
with a permanent marker on the glass cover-slip. FFPE blocks corresponding to each 
H&E slide were then cut (5-10 sections, each 10 μm thick).  Microdissection of the 
tumour cells was then completed. 
 
2.4.4 DNA extraction from microdissected FFPE blocks:  The Qiagen QIAamp DNA 
FFPE kit was used to extract genomic DNA from the FFPE tisues as per the 
manufacturer’s instructions.  A volume of 160μl of deparifination solution was added 
to each sample in an eppendorf tube before centrifugation and incubation at 56°C.  
180μl of buffer ATL (lysis buffer for purification of nucleic acid, Qiagen) and then 20μl 
of proteinase K was added followed by incubation at 56°C and then 90°C.  The tubes 
were then transferred to a 2ml safe-lock microcentrifuge tube and placed into the 
QIAcube for DNA extraction.  Finally, DNA quantification of each sample was 
established with the Qubit 2.0 fluorometer and the samples were stored at 4°C. 
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2.4.5 Ion Torrent sequencing:  The ion torrent next generation sequencer (Life 
Technologies), a validated technique 252 253, was used to sequence the DNA for each 
sample according to the manufacturer’s protocols.  10ng of DNA for each sample 
was used for library preparation with the Ion AmpliSeq Cancer Hotspot Panel v2 (Life 
Technologies).  This panel gives 207 amplicons covering 2,800 COSMIC mutations 
from 50 oncogenes and tumour suppressor genes, including KRAS, p53, CKDN2A 
and SMAD4.  No more than sixteen samples were processed at a time.  Each library 
was barcoded with Ion Express Barcode Adaptors 1-16 kit and then purified with 
Agencourt AMPure XP reagent (Life Technologies).  Following qPCR of each sample 
for quantification, all samples were combined in equal concentration into a single 
pool of 25μl.  Template preparation was performed on the Ion PGM OneTouch 
system (Life Technologies) resulting in template positive ion sphere particles (ISPs).  
After quality control with the Ion Sphere Quality Control Kit (Life Technologies) to 
ensure a 10-30% template to bead ratio, the template positive ISPs were enriched on 
the Ion OneTouch ES system (Life Technologies).  Sequencing primer and Ion PGM 
Sequencing 200v2 Polymerase were added to the enriched ISPs before loading onto 
a chip from the Ion 314 Chip Kit v2 (Life Technologies) and sequencing the samples 
on the Ion PGM System.  Data analysis was carried out with Torrent Suite Software 
(Life Technologies) to generate sequence reads, trim adapter sequences and filter 
and remove poor signal-profile reads. 
 
2.4.6 Power calculation:  From the DNA analysis of the FFPE tissues we would 
consider a difference in a genetic mutation between the two groups of 60% to be 
clinically relevant.  We estimated the sample size needed to detect a 60% difference 
at 90% power and 5% level of confidence to be 14 in each group with the calculation 
below.  Where π1 is 85%, the percentage of patients in the early recurrence group 
for which this mutation would be considered clinically relevant and π2 is 40% of 85% 
(a 60% reduction). 
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N in each group = f(α, β) x ((π1 x (100 – π1) + π2 x (100 – π2))/ (π1-π2)2) 
 
2.4.7 Blood Samples:  Patients were invited to donate blood prior to their pancreatic 
resection.  Blood was taken and processed as follows: 
 
2.4.7.1 For DNA sequencing:  An EDTA tube of whole blood was collected and 
immediately processed to extract DNA using the QIAamp DNA Blood Mini Kit 
(Qiagen) according to the manufacturer’s protocol.  In brief, proteinase K and Buffer 
AL (Qiagen) was added to 200μl of each sample and incubated at 56°C.  After the 
addition of 100% ethanol, the sample was applied to the QIAamp Mini spin column 
and centrifuged.  The sample was also centrifuged after the addition of Buffer AW1, 
Buffer AW2 and Buffer AE (all Qiagen).  DNA quantification of each sample was 
established with the Qubit 2.0 fluorometer and the samples were stored at -20°C.  
Sequencing of DNA was carried out with the ion torrent next generation sequencer 
as described above. 
 
2.4.7.2 For circulating tumour cells (CTCs) analysis:  7.5mls of whole blood was 
collected in a CellSave (Veridex, NJ, USA) preservative tube. The samples were then 
processed in our laboratory within 48 hours using the bead-based fluorescence 
CellSearch system (Veridex, NJ, USA) according to the manufacturer’s protocol.  
After centrifugation, the sample was placed in the CellSearch system.  The plasma 
was aspirated and a buffer containing ferrofluid nanoparticles with antibodies to 
target EpCam was added.  Magnets were then used to draw the ferrofluid particles to 
the side of the tube so that unlabelled cells were aspirated.  The magnets were 
removed and target cells were resuspended in a buffer containing permeabilising and 
staining reagents.  The epithelial cells were stained with antibodies labelled with 
phycoerythrin to target cytokeratins 8, 18 and 19.  To distinguish CTCs from 
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leucocytes, allophycocyanin, labelled antibodies to CD45, were also used.  
Additionally, DAPI to stain cell nuclei and to distinguish viable cells from nonspecific 
debris was added.  The epithelial enriched sample was then placed in a Magnest that 
attracts the magnetically labelled cells.  Samples were then scanned on the 
CellTracks analyzer II fluorescent microscope (Veridex, NJ, USA) for analysis. The 
cells were evaluated for CTCs independently by 2 operators. 
 
2.4.7.3 For microRNA (miRNA) analysis – RNA extraction:  Blood was collected into 
two EDTA tubes and immediately put on ice.  Samples were processed immediately.  
After centrifugation, the plasma was aspirated and placed in eppendorf tubes for 
storage at -80°C.  RNA extraction was performed at a later date using the miRNeasy 
serum/plasma kit (Qiagen) according to the maufacturer’s protocol.  For each sample, 
a total of 1ml of thawed plasma was used.  QIAzol lysis reagent (Qiagen) and 
chloroform, was added to each sample.  Following cold centrifugation and mixing 
with 100% ethanol each sample was added to an RNeasy MinElute spin column 
(Qiagen) and centrifuged.  This step was repeated so that all 1ml of each original 
plasma sample was processed through the same spin column.  Each spin column 
was washed with Buffer RWT, Buffer RPE (Qiagen) and 80% ethanol.  After the 
addition of RNase-free water, the RNA was eluted.  RNA quantification was 
established with the NanoDrop 2000c UV-Vis Spectrophotometer (Thermo Scientific).  
RNA was stored at -80°C. 
 
microRNA (miRNA) analysis:  miRNA analysis of the extracted RNA was performed 
using the NanoString nCounter system (NanoString Technologies, Seattle, WA). This 
method enables multiplexed direct digital counting of miRNA molecules using colour-
coded barcodes.  The method measures a total of 800 probes including both 
endogenous human-associated miRNAs as well as viral miRNAs that are expressed 
in human cells.  The hybridization method used directly interrogates target 
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sequences, avoiding the need for bias-prone amplification steps, even for low-
abundance transcripts. Further, measurement is achieved using the digital detection 
of uniquely bar-coded probes, providing absolute quantification 254.  3μl of each 
sample was used following purification of the RNA with Amicon 3kD cellulose 
columns to remove impurities.  Each RNA sample was added to the miRNA-tag 
ligation reaction.  Following ligation, samples were diluted 1:10, and 5ul of each 
miRNA-tag sample (equivalent to 10ng total RNA) were added to hybridizations.  
Excess probes were removed using two-step magnetic bead based purification on 
the nCounter Prep Station (nanoString Technologies). Abundances of specific target 
molecules were quantified on the nCounter Digital Analyzer by counting the individual 
fluorescent barcodes and assessing the target molecules. For each assay, a high-
density scan encompassing 600 fields of view was performed. The data was 
collected using the nCounter Digital Analyzer.  miRNA data analysis was performed 
using the nSolver software analysis, (nanoString Technologies).  The serum miRNA 
profiling data was normalized using the average signals obtained from a spike-in 
control (Lyophilized C. elegans miR-39 miRNA mimic, Qiagen), and miRNAs that 
gave significant hybridization signals were used for downstream analysis. 
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CHAPTER 3: 
A Literature review of potential biomarkers in pancreatic cancer 
 
3.1 Introduction: 
An early diagnosis of pancreatic cancer is often delayed due to the late onset of 
symptoms and a limited use of current imaging modalities.  Further, many clinical 
modalities such as EUS and FNA are invasive procedures with resultant risks to the 
health of a patient.  Following the diagnosis of PDAC there are few options for 
monitoring disease progression during oncological management or for detecting 
disease recurrence following pancreatic resection.  The gold standard being interval 
CT scans and blood Ca 19-9 levels. However, as discussed above these have limited 
sensitivities and specificities.  After curative surgical resection and adjuvant 
chemotherapy, it is not yet possible to determine patient prognosis.  Many develop 
disease recurrence within 12 months where as others do not develop disease 
recurrence for at least two years and around 5% have no evidence of PDAC at 5 
years post resection.  In order to improve these issues there is a need to develop a 
‘liquid biopsy’, a blood based biomarker, able to detect PDAC and to monitor its 
progression with high sensitivity and specificity.  Much recent work has concentrated 
on three potential biomarkers including circulating tumour cells (CTCs), cell-free DNA 
and micro RNAs. 
 
3.2 Circulating tumour cells (CTCs): 
In 1869, Thomas Ashworth, detected tumour cells in the blood of a patient with 
metastatic cancer 255. These cells, termed “circulating tumour cells” (CTCs), have 
since been of great interest in tumour biology research. CTCs are cells which 
circulate through the bloodstream, having been formed by tumour-induced 
angiogenesis 256. This blood-borne dissemination of tumour cells from the primary 
site to distant organs may lead to metastatic disease. Levels of CTCs in the 
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peripheral blood are low, for example only one cell per 105-107 with respect to 
mononuclear cells and therefore their detection is extremely challenging. Recently, 
the development of an automated detection system “CellSearch” (Veridex, NJ, USA), 
validated in 2007 257 and FDA approved, has enabled us and others to focus on CTC 
blood levels in patients with various tumour types 258, 259.   
 
CTCs are an independent predictor of progression-free survival and overall survival 
in metastatic breast cancer 260-262, colorectal cancer 263, 264, castrate-resistant prostate 
cancer 265 and in small-cell-lung-cancer 266. However, there are limited data on CTCs 
in PDAC.  A literature search for relevant studies using the search terms ‘CTC’ OR 
‘circulating tumour cells’ AND ‘pancreatic cancer’ was conducted on PubMed, 
Embase, Web of Science, Cochrane Library and Google Scholar databases.  Ren et 
al. 267 measured two or more CTCs (mean 16.8±16.0) in 7.5mL of peripheral blood in 
80.5% (33/41) of patients with advanced PDAC. No CTCs were detected in 20 
healthy donors (p<0.01). After seven days of the first cycle of 5-FU chemotherapy, 
only 29.3% (12/41) of PDAC patients had more than two CTCs in 7.5mL of peripheral 
blood. De Alburquerque et al. 268 developed an immunomagnetic/RT-PCR assay and 
were able to detect CTCs in 47.1% (16/34) of PDAC patients, compared to none in 
healthy controls (n=40). Additionally, a shorter progression-free survival was 
observed for patients who had at least one CTC detected compared to those who 
were CTC negative.  Yu et al. 269 used CTCs from an endogenous mouse PDAC 
model, to identify Wnt2 as a possible therapeutic target.  A meta-analysis was 
conducted of nine cohort studies analysing CTCs in pancreatic cancer patients. 270   
In a total of 623 patients, 43% had positive CTCs from peripheral blood samples.  
These CTC-positive patients had significantly worse progression-free survival than 
CTC-negative patients (HR 1.89, 95% CI 1.25-4.00, p<0.001) and showed worse 
overall survival (HR 1.23, 95% CI 0.88-2.08, p<0.001).  However, others have failed 
to correlate survival and CTCs Indeed, in a recent study 271, only five of 20 patients 
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(25%) had positive CTCs in the systemic circulation and these patients did not have 
shorter disease-free or overall survival compared to CTC-negative patients. 
 
Further analyses of CTCs in PDAC will provide new insights into its molecular biology, 
and in particular a better understanding of the metastatic process and the alterations 
that drive disease spread. They may well have a role in the initial diagnosis, detection 
of recurrent disease or aid in the selection of targeted adjuvant therapy for these 
patients.  However, it is not clear whether CTCs will prove as beneficial biomarkers 
as in other cancers as small numbers are captured compared to other solid tumours.  
Further, to date, studies include small numbers of patients and most find CTCs in 
less than half of PDAC patients irrespective of disease stage. 
 
3.3.1 Cell-free DNA (cfDNA): 
In 1948, Mandel and Metais published the first article to describe the occurrence of 
circulating nucleic acids in human plasma 272. Thirty years later, in 1977, Leon et al. 
reported elevated levels of circulating DNA in the serum of cancer patients 273 and in 
1989, plasma DNA was shown to be higher in patients with various malignancies, 
compared to healthy individuals 274. Gradually with improvements in DNA detection, 
the oncogenetic importance of cfDNA has been realised and several cancer-specific 
mutations and microsatellite alterations have been identified in plasma DNA 275-277. 
Subsequently, the widespread availability of polymerase chain reaction (PCR) 
techniques has allowed for a rapid increase in the ability for cfDNA detection. 
Emerging evidence suggests that identifying specific genetic and epigenetic 
mutations in cfDNA, may detect specific tumours, as well as monitor responses to 
treatment. Thus there is the potential for cfDNA to have significant clinical 
implications as a non-invasive biomarker to aid diagnosis, prognosis, monitoring and 
personalized therapy.  A literature search for relevant studies using the search terms 
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‘cell free DNA’ OR ‘cfDNA’ AND ‘pancreatic cancer’ was conducted on PubMed, 
Embase, Web of Science, Cochrane Library and Google Scholar databases. 
 
3.3.2 Origin and composition of cfDNA: 
Circulating cfDNA is extracellular DNA, which occurs both in plasma and serum. The 
cfDNAs are mostly double-stranded molecules, consisting of small fragments of 70-
200 base pairs (bp) up to larger fragments with molecular weights of 21kb 278, 279.  It is 
thought that cfDNA is actively released from all living cells, as a part of normal 
metabolism 280. However, 4 to 40 times greater levels are seen in patients with 
cancer 279. For example, in colorectal cancer, it is estimated that up to 3.3% of the 
tumour DNA is fed into the circulation on a daily basis, depending on Dukes’ Stage 
281. cfDNA is also increased in other physiological and pathological conditions, 
including exercise, smoking, inflammatory disease, critical illness, sepsis and trauma 
282-284. Therefore there has been much postulation over the origins of circulating 
cfDNA. In physiologically active and pathological states, there can be a release of 
cfDNA from apoptosis; necrosis; direct release from viable cells and from the lysis of 
circulating tumour cells (CTCs).  Apoptosis is programmed for a large number of cells 
on a daily basis. In cancer, the high cell turnover seen, leads to increased 
programmed cell death and thus may explain the higher concentrations of plasma 
cfDNA 279. Apoptotic cell death is also characterized by fragments of around 180-720 
bp, similar to a large proportion of cfDNA identified in plasma 285. Moreover, 
chloroquine, is able to induce a low level of apoptosis, and its application has been 
shown to increase cfDNA concentration 286.  Neoplastic cells undergo rapid 
enlargement and start to outgrow their blood supply.  This results in hypoxia and 
leads to necrosis.  Necrotic cells are phagocytosed by macrophages and 
subsequently, the ingested cell components, including tumour DNA fragments, are 
released into the circulation 281.  Normal cells close to the tumour may also become 
necrotic, leading to increased levels of ‘normal’ DNA in the circulation by the same 
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process.  The tumour may also actively release DNA into the bloodstream. Ex-vivo 
experiments on lymphocytes have shown a release of newly-synthesised DNA that is 
not a result of cell death 287. Experiments using a rat model of colorectal cancer found 
increased levels of both tumour and non-tumour cfDNA in the early stages of the 
disease. The authors suggested that when there is minimal necrosis, there is an 
enhanced turnover and an increase in the active release of DNA from both cancer 
cells and normal adjacent tissue 288. The biological reasons behind these theories 
remain unclear.  One further hypothesis for the increase of cfDNA in cancer is due to 
the release of DNA fragments from CTCs.  CTCs are due to the blood-borne 
dissemination of tumour cells and are thought to be involved in the development of 
metastatic disease. They have been detected in a number of tumour types and their 
lysis may contribute to cfDNA 289.  
 
Once released into the circulation, cfDNA has a short half-life of between 4 minutes 
to several hours 290, 291 and it is thought that the liver, spleen and kidneys all play a 
role in its clearance. DNA may exist in the blood within protein bound complexes, 
involving albumin, immunoglobulins, fibronectin, lactoferrin, lysozyme and serum 
amyloid P component 292. Additionally, cfDNA can be associated with the surface of 
haematopoietic cells either as part of a complex or directly bound to the cell surface 
293.  
 
3.3.3 cfDNA as a biomarker for cancer: 
Currently, there is debate as to whether total cfDNA levels could be used as a 
diagnostic marker for malignancy, as generally its sensitivity for cancer detection is 
low 294. However, identifying tumour-specific genetic and epigenetic changes in 
cfDNA, including gene mutations; loss of heterozygosity (LOH); methylation 
alterations; and microsatellite alterations may be more specific. Epigenetic changes 
are some of the earliest events in malignant transformation and thus their detection in 
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blood samples has the potential to lead to early clinical biomarkers for various 
cancers.  
Gene mutations: Tumour-specific gene mutations, including mutations in tumour 
suppressor genes and oncogenes have been identified from cfDNA. Many studies 
have shown an agreement between mutations found in tumour tissue and those 
found in cfDNA. Point mutations have been found in a number of important genes 
including KRAS and P53.   
Loss of heterozygosity: PCR-based assays have allowed for the detection of LOH. 
Analysing cfDNA in 388 breast cancer patients showed a significant correlation 
between LOH in five polymorphic markers and tumour stage, tumour size and lymph 
node metastasis. Others, have investigated LOH at chromosomal location 18q in 
colorectal cancer, a location associated with a number of tumour suppressor genes.  
There are as many studies showing no correlation between LOH and prognosis in 
tumour tissue 295 296 297 as those that have found a relationship 298 299 300. Therefore, 
there is minimal research looking at LOH in peripheral blood.   
Methylation alterations: DNA methylation is an important physiological process active 
in all cells and required for many cellular events. Methylation occurs at CpG islands, 
which are mainly found at the promoter areas of genes. Abnormal methylation, such 
as the hypermethylation of a promoter region of a tumour suppressor gene, results in 
gene silencing 291. Hypomethylation leads to increased mutation rates and 
chromosome instability 301. The hypermethylation of numerous genes, including APC 
and p16, has been identified and may be involved in the development of cancer. 
Hypermethylated genes found in tumour tissues, can also be detected in cfDNA 302. 
Microsatellite alterations: Microsatellites are short DNA sequences with lengths of 1-6 
nucleotides, which are repeated up to sixty times. There are thousands of these 
areas in the genome. PCR techniques are able to detect alterations in these 
microsatellite areas, including the deletion of one of the alleles, new microsatellite 
areas or a LOH. Several studies have successfully identified microsatellite alterations 
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in cfDNA in various cancers 291 and there is evidence to suggest that these 
alterations can be found at a very early stage of disease.  
 
3.3.4 cfDNA in PDAC: 
Many cfDNA studies have investigated KRAS mutations from blood samples of 
PDAC patients (Table 3). Uemura et al. 303  looked at KRAS mutations in both tumour 
tissue and plasma of 28 patients with PDAC. Ninety-three percent of patients had 
KRAS mutations in pancreatic tumour tissue, as opposed to only 35% in the plasma. 
Other authors 304-307 have found plasma KRAS mutations in 36-73% of PDAC 
patients. Although these percentages vary, likely due to the different methods used, 
these studies also found that mutations occur more frequently in PDAC patients than 
those with chronic pancreatitis (CP; 0-20%). Combining the detection of KRAS 
mutations with a raised CA-19-9 accurately diagnoses PDAC with a sensitivity of 
67%-98% and specificity of 77%-97% (Table 3). Chen et al. 308 found that patients 
with inoperable PDAC and KRAS mutations in plasma DNA, have significantly worse 
survival compared to those with wild type KRAS (3.9 vs. 10.2 months). Furthermore, 
Dabritz 309 correlated the presence of mutated KRAS in the plasma of patients with 
pancreatic cancer with CT findings. 15/38 patients (39%) were found to have plasma 
KRAS mutations. Only 9% of patients with complete remission of disease on CT had 
KRAS mutations. Detectable KRAS mutations in the plasma were clearly associated 
with corresponding CT scans with signs of progressive disease in 75%. When 
combined with CA 19-9 levels, 92% of patients with KRAS mutations and an elevated 
CA 19-9 level had progressive disease on CT as opposed to only 33.3% of those 
with KRAS wild-type and normal CA 19-9 levels. However, others have failed to 
correlate KRAS mutations with survival. 310  Other authors have concentrated on 
methylation abnormalities in cfDNA. Park et al. 311 found altered methylation in 81.3% 
of PDAC patients, compared to 61.5% of those with CP and 3.5% of healthy controls. 
Although this showed limited differences between PDAC and CP, Liggett et al. 312 
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were able to discriminate between the presence of neoplasia and inflammation with a 
sensitivity of 91.2% and a specificity of 90.8%. Others have used models of 5 
promoter CpG sites to discriminate PDAC from healthy individuals with reasonable 
results (e.g. Pederson et al. 313 obtained a C-statistic of 0.76 [C-statistic >0.7 
indicates good predictive power of the model]; and Melnikov et al. 314 found 76% 
sensitivity and 59% specificity). 
 
Whilst all these studies have small numbers of patients and use a variety of sampling 
and analytical techniques for determining cfDNA changes, it is encouraging that 
many have found cfDNA to be clinically useful in PDAC. Although this could partly be 
due to publication bias, KRAS mutations and methylation alterations appear more 
frequent in the blood of patients with PDAC compared to controls. Furthermore, 
combining cfDNA results with other markers, such as CA 19-9, the sensitivity and 
specificity of detection markedly improves. Finally, cfDNA may be a good indicator of 
prognosis and disease progression.  Despite this, few well designed trials have 
rigorously examined the role of cfDNA as a biomarker for cancer detection, prognosis 
or treatment response.
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Author / 
Reference 
Year Patient population DNA 
source 
cfDNA mutation Significant Findings 
Kinugasa et al.307 2015 66 PDAC Serum KRAS KRAS mutations in 54.5% 
Park et al. 311 2012 16 PDAC, 13 CP, 29 
healthy 
Plasma Methylation Altered methylation in PDAC compared to CP and compared to healthy controls 
Dabritz 309 2012 38 PDAC Plasma KRAS mutations and CT 
findings 
KRAS mutations in 39% of PDAC patients.. Mutations associated with signs of progressive 
disease. 
Pederson et al. 313 2011 Phase I: 132 PDAC,  
60 healthy Phase II: 
240 PDAC; 240 
healthy 
Whole 
blood 
Methylation Prediction model of 5 CpG sites discriminated PDAC from controls  
Liggett et al. 312 2010 30 PDAC, 30 CP, 30 
healthy  
Plasma Methylation 91.2% sensitivity and 90.8% specificity for PDAC vs. CP differentiation 
Chen et al. 308 2010 91 unresectable 
PDAC 
Plasma  KRAS mutations KRAS mutations in 33% of PDAC patients .  Worse survival in those with mutations  
Dabritz et al. 304 2009 56 PDAC, 13 CP Plasma  KRAS mutations More KRAS mutations in PDAC vs CP. Add CA 19-9 = 91% sensitivity for cancer diagnosis. 
Melnikov et al. 314 2009 30 PDAC, 30 healthy Plasma Methylation Prediction model of 5 promoters has 76% sensitivity and 59% specificity for PDAC 
detection. 
Uemura et al. 303 2004 28 PDAC Tumor and KRAS mutations KRAS mutations in 35% of PDAC patients’ plasma 
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Table 3: Studies detecting cfDNA in patients with PDAC.  PDAC: pancreatic ductal adenocarcinoma; CP: chronic pancreatitis;  
 
  
Plasma 
Dai et al305 2003 15 PDAC, 10 CP Plasma KRAS mutations KRAS mutations in 73% of PDAC patients vs 20% of CP patients.  
 KRAS + CA 19-9 = 66.67% sensitivity and 97% specificity for cancer detection. 
Maire et al. 306 2002 47 PDAC, 31 CP Serum KRAS mutations KRAS mutations in 47% of PDAC patients vs 13% of CP patients .   
KRAS + CA 19-9 = 98% sensitivity and 77% specificity. 
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3.4 MicroRNAs (miRNA): 
Focussing on tiny sequences of RNA (miRNAs) in the blood may allow the discovery 
of more sensitive and specific cancer diagnostic/prognostic tools. miRNAs are a 
class of small non-coding RNAs of ~19-25 nucleotides in length, that are involved in 
the post-transcriptional  regulation of a large number of genes and can affect many 
different biological pathways.  In our laboratory, from pancreatic cell-lines and tumour 
tissue, we have previously identified 3 miRNAs (miR-21, miR-23a, and miR-27a) that 
act as cooperative repressors of a network of tumor suppressor genes that includes 
PDCD4, BTG2, and NEDD4L315. Inhibition of these 3 miRNAs had synergistic effects 
in reducing proliferation of PDAC cells in culture and growth of xenograft tumors in 
mice. The level of inhibition was greater than that of inhibition of miR-21 alone. In 91 
PDAC samples from patients, high levels of a combination of miR-21, miR-23a, and 
miR-27a were associated with shorter survival times after surgical resection (Figure 
4). 
 
A literature search for relevant studies using the search terms ‘circulating micro 
RNAs’ OR ‘circulating miRNA’ AND ‘pancreatic cancer’ was conducted on PubMed, 
Embase, Web of Science, Cochrane Library and Google Scholar databases.  Some 
studies have now indicated that blood-based miRNAs are an impending clinical utility 
as diagnostic and/or prognostic biomarkers for PDAC (Table 4). Kong et al. 316 
showed elevated serum miR-196a levels strongly correlated with poor survival and 
advanced stage disease in PDAC, and could be used to aid selection of surgical 
candidates.  However, others have failed to find a survival correlation between PDAC 
patients with dysregulation of those miRNAs found to differ between PDAC and 
controls. 317  Bauer et al. 318 performed a large study of the PDAC miRNome in blood. 
They compared the differential expression of miRNAs between PDAC vs. normal 
pancreas / chronic pancreatitis in tissue specimens, and between PDAC vs. healthy 
controls / chronic pancreatitis in blood samples. The combined analysis revealed that 
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10 miRNAs (miR-148a, 216a, 217, 181a, 181c, 324-5p, 146a, 210, 345, 574-5p) 
were able to differentiate between PDAC vs. normal / inflammed pancreas 
(P=0.0006) in tissue and blood specimens. When assessing miRNAs in blood 
samples only, 36 miRNAs were able to distinguish PDAC vs. normal with high 
sensitivity and specificity (0.973 and 0.950 respectively). Therefore, combinations of 
miRNAs may prove more accurate at diagnosing and/or predicting outcome in PDAC 
patients. 
 
 
Figure 4: Overall cancer-specific survival among PDAC patients depending on tumoral miRNA expression 
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Author / 
Reference 
Year No. of 
Patients 
Blood Type Used miRNA expression in 
PDAC patients 
Significance 
Abue et al. 319 2015 32 PDAC 
12 IPMN 
30 HC 
Plasma +miR‑ 483-3p 
+miR‑ 21 
 
 Upregulated in PDAC vs HC 
 miR-483-3p upregulated in PDAC vs IPMN 
Komatsu et al. 320 2015 71 PDAC 
67 HC 
Plasma +miR-223  Upregulated in PDAC vs HC (p<0.0001) 
Ganepola et al. 321 2014 8 PDAC 
11 HC 
Plasma +miR-642b-3p,  
+miR-885-5p  
+miR-22-3p 
 All up-regulated in PDAc vs HC 
 Sensitivity of 91% and specificity of 91% for discriminating PDAC and HC 
Carlsen et al. 317 2014 48 PDAC 
47 HC 
Plasma +miRNA-375  Upregulated in PDAC vs HC 
 No correlation with survival 
Wang  
et al.  
322 
2013 129 PDAC,  
103 BPD, 
60 HC 
 
Peripheral blood 
mononuclear cells 
+miR-27a-3p 
+miR-16-5p 
+miR-15b-5p 
 
 
 All up-regulated in PDAC vs. BPD and PC vs. HC  
 Multivariate logistic regression model showed miR-27a-3p was able to discriminate PC 
from BPD and HC. 
 Combination of miR-27a-3p and serum CA19-9 levels provides higher diagnostic 
accuracy with 85.3% sensitivity and 81.6% specificity (AUC 0.886; 95% CI, 0.837–
0.923%). 
  80 PDAC  
129 HC  
 +RNU2-1f 
 
 Upregulated PDAC vs HC 
Bauer et al. 
318 
2012 45 PDAC  
38 CP  
Whole  Blood 87 miRNAs 
differentially 
 With statistical learning techniques, high sensitivity and specificity (AUC values 0.973 
and 0.950) for discriminating PDAC or CP from HC. 
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33 HC  expressed between 
PDAC and HC 
 Unable to discriminate PDAC and CP. 
Liu et al.  
323 
2012 197 PDAC  
82 CP  
158 HC  
Serum +miR-20a  
+miR-21  
+miR-24  
+miR-25  
+miR-99a  
+miR-185  
+miR-191 
 7 miRNA–based biomarker distinguishes PDAC from HC (AUC 0.992); and PDAC from 
CP (AUC 0.993). 
 miR-21 levels associated with overall PDAC survival. 
Morimura  
et al. 
324 
2011 36 PDAC  
30 HC  
Plasma +miR-18a  miR-18a significantly upregulated in PDAC (AUC 0.9369). 
 miR-18a levels lower in post-operative samples, than in pre-operative samples 
(P=0.0077). 
Liu et al.  
325 
2012 140 PDAC  
111 CP  
68 HC  
Plasma +miR-16 
+miR-21 
+miR-55 
+miR-181a 
+miR-181b 
+miR-196a 
+miR-210 
 miR-16, miR-196a and CA19-9 discriminate PDAC from CP and HC (AUC 0.979; 
sensitivity, 92.0%; specificity, 95.6%); and discriminates PDAC from CP (AUC 0.956; 
sensitivity, 88.4%; specificity, 96.3%). 
LaConti  
et al. 
326 
2011 6 PDAC  
8 HC  
12 Other GI 
Plasma +miR-100a  
+miR-10 
 Panel of 9 miRNAs (miR-100a, miR- 10, miR-155, miR-199, miR- 221, miR- 21, miR- 
210, miR- 223, miR- 16) distinguishes PDAC from HC and other GI cancers. 
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cancers  
Li et al.  
327 
2010 45 PDAC  
11 CP  
32 HC  
Serum +miR-200a 
+miR-200b 
 PDAC distinguished from HC with miR-200a and miR-200b (AUC 0.861 and 0.85 
respectively). 
 No difference in miRNA expression between PDAC and CP. 
Wang et al.  
328 
2009 49 PDAC  
36 HC  
Plasma +miR-21 
+miR-210 
+miR-155 
+miR-196a 
 Combination of 4 miRNAs detects PDAC vs. HC with AUC 0.82 (95% CI, 0.70-0.94). 
Kong et al. 329 2010 35 PDAC  
15 CP  
15 HC  
Serum +miR-21 
+miR-155 
+miR-196a 
 
 miR-21 can differentiate PDAC from CP (P<0.003) and from HC (P<0.001). 
 miR-155 and miR-196a can differentiate PDAC and CP from HC. 
Table 4:  Studies detecting miRNA in patients with PDAC. PDAC, pancreatic ductal adenocarcinoma; IPMN, intraductal papillary mucinous neoplasm; CP, chronic pancreatitis; HC, healthy control; 
BPD, benign pancreatic disease; +, up-regulated; -, down-regulated; AUC, area under curve. 
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3.5 Summary: 
PDAC is a lethal disease and new techniques are urgently required to enable earlier 
diagnosis and the identification of disease recurrence in order to improve survival. A 
deeper understanding of the molecular alterations in PDAC will allow the 
development of novel detection and therapeutic strategies 330. The ideal test would 
be one which is non-invasive and inexpensive, which could be used clinically as 
diagnostic, predictive and prognostic biomarkers.  Research has focused on blood 
based biomarkers and over the last 5 years, we have seen promising results from 
measuring CTCs, tumour-specific nucleic acid alterations and circulating miRNAs in 
PDAC patients. However, there are considerable obstacles to detecting many of 
these biomarkers, as they are present at extremely low concentrations in the blood 
and the technology required is expensive and time-consuming. Furthermore, there is 
no standardised validation for these tests and thus results from these early studies 
are variable. The numerous genetic alterations found in PDAC adds to the 
complexity, as we are unsure how to act on the results.  Research involving these 
serum biomarkers needs to be consolidated in order to develop multiplex assays. 
This will allow the future improved detection of this disease and hopefully lead to 
more personalised anti-cancer therapy.  Most research has investigated the use of 
these markers as a means of detection of PDAC compared to healthy controls or 
those with benign pancreatic disease with limited data on PDAC prognosis. 
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CHAPTER 4: 
Results and Discussion 
 
4.1 Surgical technique to reduce recurrence rates 
 
4.1.1 HYPOTHESIS 
The literature review conducted identified CTCs as a potential biomarker in PDAC, in 
particular, a biomarker proven to identify invasive cancers with metastatic potential in 
other solid tumours.  As discussed in the introduction, the no-touch technique may 
potentially prevent the dissemination of cancer cells (or CTCs) into the circulation.  A 
study was therefore planned in order to test whether the no-touch technique reduces 
PDAC recurrence, using CTCs as a biomarker. 
 
We hypothesised that the no-touch PD technique will reduce the number of 
circulating tumour cells released into the circulation and reduce the disease 
recurrence rate in PDAC patients compared to the standard PD technique. 
 
4.1.2 RESULTS 
Based on the availability of the CellSearch system to perform the assay, and our 
power calculation, 12 patients with a pre-operative suspicion of PDAC were 
randomized into this study (ST-PD n=6 (Group I); NT-PD n=6 (Group II)). All patients 
had Stage II disease (potentially resectable) and none had received neo-adjuvant 
chemotherapy. There were no differences between the 2 groups with regards to age, 
operative time, length of hospital stay, complication rate, lymph-node ratio or tumor 
characteristics (Table 5). Only 1 patient (in group I) required a peri-operative blood 
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transfusion (2 units). For pancreatic duct reconstruction, 5 patients in each group had 
a longitudinal ventral pancreaticojejunostomy anastomosis (LVPA) and 1 in each 
group had a pancreaticogastrostomy (PG).  Major complications included 1 biliary 
leak in group I, and 1 pancreatic leak (PG anastomosis) in group II. Both cases were 
treated conservatively.  All tumours were confirmed histologically as PDAC and 
AJCC Stage IIB (pT3, N1, M0).  R1 resection was defined as cancer cells within 1 
mm of a circumferential or transection margin. A negative resection margin (R0) was 
achieved for six patients (50%) with three in each group having R1 medial resection 
margins.  
 
Prior to resection of the pancreatic head, there was no difference in the number of 
CTCs between the 2 groups (group I, range 0-4 vs. group II, range 1-6; P=0.306). 
Following resection, an increase in the number of CTCs was seen in 5/6 (83%) 
patients in group I, but 0/6 in group II (P=0.003; Table 6).  
 
The median follow-up period for the entire cohort was 14.6 months (range 10.5-27.9 
months). At the end of follow-up, there were 7 deaths and 5 survivors.  Three 
patients in the ST-PD group (50%) and two patients in the NT-PD group (33%) 
developed disease recurrence in the liver (n=2) and lung (n=3). There was no 
difference in disease-free survival (DFS) between the two groups (p=0.421, Figure 
5). Median overall survival (OS) was 13.0 months (95% CI 10.1-15.9) in group I and 
16.7 months (95% CI 12.6-20.8) in group II (p=0.328; Figure 6).  
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 Group I, n=6 Group II, n=6 p-value 
Median age, years 66.3 65.6 0.92  
Median operative time, 
hours 
4 3.3 0.27  
Median length of stay, 
days 
17 16.2 0.32  
Major complications 1 1 1.0 b 
Pathological tumour 
stage 
pT3 (100%) pT3 (100%) 1.0  
Mean tumour size, mm 35 37 0.81  
Mean lymph node ratio 0.29 0.38 0.41  
Positive resection 
margin 
50% 
(all medial margin) 
50% 
(all medial margin) 
1.0  
Perineural invasion 100% 100% 1.0  
Lymphovascular 
invasion 
100% 100% 1.0  
Table 5: Clinicopathological characteristics of patients undergoing pancreaticoduodenectomy for pancreatic cancer.  
Group 1 = standard pancreaticoduodenectomy. Group II = no-touch technique pancreaticoduodenectomy.   
  
 92 
 
Table 6: Number of PV CTCs before and after resection for each patient.  CTCs, circulating tumor cells; PV, portal 
vein;  Group 1 = standard pancreaticoduodenectomy. Group II = no-touch technique pancreaticoduodenectomy; 
aWilcoxon Signed Rank test Pearson; bChi-Squared test, 2-tailed 
 
  
 
Patient Group 
 
 
No. of CTCs  
Before Resection 
 
No. of CTCs  
After Resection 
 
Difference 
 
Increase in CTCs after 
resection? 
Group I 
 
Patient 1 0 8 +8 Y 
Patient 2 1 2 +1 Y 
Patient 3 1 3 +2 Y 
Patient 4 1 1 0 N 
Patient 5 2 3 +1 Y 
Patient 6 4 6 +2 Y 
Group II 
 
Patient 1 3 2 -1 N 
Patient 2 1 1 0 N 
Patient 3 3 3 0 N 
Patient 4 1 1 0 N 
Patient 5 1 0 -1 N 
Patient 6 6 6 0 N 
P 
Value 
 
0.306a 0.751a - 0.003b 
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Figure 5: Kaplan-Meier curve of disease-free survival (DFS) comparing the 'no-touch' isolation 
pancreaticoduodenectomy to standard PD. Comparison between groups was made by log-rank test 
 
 
Figure 6:  Kaplan-Meier curve of overall survival (OS) comparing the 'no-touch' isolation pancreaticoduodenectomy 
to standard PD. Comparison between groups was made by log-rank test   
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4.1.3 DISCUSSION 
This is the first study to examine CTC numbers in the portal venous circulation during 
PD for PDAC. The NT-PD has since been adopted as the standard for pancreatic 
head resection in our patients with PDAC. There was a significant increase in the 
number of CTCs following a ST-PD, but not following the NT-PD method. Although 
the NT-PD group trended towards better DFS and OS, there was no significant 
difference.  The log-rank test performs poorly with small sample sizes and so this 
may be a Type II error.331  The 'no-touch' (NT) isolation technique was first described 
as a way of preventing the spread of cancer cells in colorectal and eye cancer by 
limiting the handling of the tumors.184, 332 In colorectal cancer (CRC), a tendency for a 
reduction in the number and time to liver metastases over 5 years has been seen 
using the NT isolation technique compared to conventional resection.185 More 
recently, the NT isolation technique has been shown to be a safe procedure for PD186, 
188 and distal pancreatectomy,333 with comparable operative morbidity and mortality. 
Furthermore, in a small pilot study,187 carcinoembryonic antigen (CEA) messenger 
RNA (mRNA) was identified in PV blood samples from 50% (5/10) of patients 
undergoing ST-PD, compared to only 13% (1/8) having NT-PD. The latter group also 
had reduced disease recurrence and a longer OS. This study provided the first 
evidence for the biological benefit of using this technique, even though mRNA levels 
were not isolated from a specific cell type.  
 
The presence of CTCs is an independent prognostic factor in metastatic breast 
cancer,260-262 CRC,263, 264 castrate-resistant prostate cancer,334 and small-cell lung 
cancer.266 The detection of CTCs is extremely difficult, as they are rare and samples 
are often contaminated by leukocytes. However, the ability to detect, enumerate, and 
characterize CTCs is an important tool for the study of the metastatic cascade and 
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the improved clinical management of cancer patients. To date, the majority of studies 
have employed the CellSearch system and this is the only system with FDA approval. 
In recent years, other reproducible methods of CTC detection and analysis have 
been developed.335 However, the CellSearch system has been shown to be the most 
reliable tool in clinical trials using CTCs as a prognostic marker.336-341  There are 
however some limitations to this system: The CellSearch system assumes that 
EpCAM-positive, panCK-positive and CD45-negative cells are CTCs.342 This is a 
limitation of this method, and therefore our study, as CTCs which are not positive for 
EpCAM and panCK will go undetected. During cancer invasion and metastasis, 
some cancer cells undergo an epithelial-mesenchymal-transition (EMT), resulting in 
the downregulation of EpCAM and some cytokeratins,343 therefore these important 
CTCs will be missed. Certainly, newer methods such as the Epispot assay 344 and 
isolation by size of epithelial tumour cells (ISET) method,345 which are both able to 
assess EpCAM-negative cells, may detect more CTCs than CellSearch. Furthermore, 
apoptotic cells produced by the tumor and released into the circulation could be 
detected as CTCs, but do not have malignant potential.346 Thus, it remains unclear 
whether the detected CTCs are functionally active and actually capable of initiating 
new metastases. In PDAC, CTCs that are cell surface marker CD24+ and CD44+, 
and also epithelial-specific antigen (ESA) positive, have been shown to demonstrate 
self-renewal, tumorigenicity and differentiation, whereas those negative for these 
markers do not.347 Subsequent work has also indentified CD133+,348 nestin,349 and c-
MET 350 as important markers for tumour metastasis. Indeed, CD133+ and CXCR4+ 
cells have been found to be essential for tumour metastasis.348 Recently, CTCs from 
a PDAC mouse model have been subjected to single-molecule RNA-sequencing.351 
This revealed an enrichment of non-canonical WNT signalling in pancreatic CTCs, 
which was found to increase their metastatic potential (e.g. enhanced anchorage-
independent tumour-sphere formation and suppression of anoikis).351 Quantifying the 
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expression of these various markers in the CTCs enumerated was beyond the scope 
of our study, but would be crucial in any follow-up investigations. 
 
Peripheral CTCs have been detected using a low cut-off (≥1 CTC/7.5 mL) in 11% of 
locally advanced PDAC patients 352 and in 40-80.5% 353, 354 with metastatic disease,8, 
11, 40 compared to none in healthy individuals and those with chronic pancreatitis. 
Whilst we did not assess CTCs in the peripheral circulation, it appears that CTCs are 
easier to detect in the portal venous circulation, even in earlier stage disease, as 
92% of our patients had ≥1 CTC/7.5 mL in the PV prior to PD. The clinical 
implications of detecting CTCs in PDAC are under investigation, however reports are 
divided regarding the association between enumeration and survival outcomes.355 
Indeed, Kurihara et al354 found that in Stage III/IV disease, CTC-positive (11/26) 
patients had worse OS compared to those that were CTC-negative (15/26). Similarly, 
Bidard et al352 demonstrated that in Stage III patients, CTC-positivity at any point 
(baseline or after 2 months chemotherapy) was associated with shorter OS (HR 2.5, 
95% CI 1.2-5.4), although CTC detection did not influence DFS. Conversely, studies 
by Khoja et al345 and Negin et al356 failed to correlate CTC number with OS or DFS in 
metastatic PDAC. Plausible explanations for these findings include the small sample 
sizes / low statistical power of many of these studies; different detection methods and 
markers used and heterogeneous patient groups.352, 355  However, most studies do 
show a trend towards an association between CTC-positivity and poor survival, thus 
their role in metastatic development is still debated.  Our power calculation was 
based on an estimation that 85% versus 20% of patients would have a rise in CTCs 
after the standard and no-touch technique respectively.  It must be noted however 
that the number of CTCs in the portal or systemic circulation before and after 
operative intervention has not been previously measured in the literature and thus 
this estimation must be considered as somewhat arbitrary.  However, in our findings 
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83% versus 0% of patients had a CTC rise post resection which is in line with our 
estimation.  This was a pilot study and can now be planned on a larger scale with 
more patients. 
 
Our study, albeit in a small number of patients, showed that NT-PD is comparable to 
ST-PD with regards to peri-operative morbidity and long-term outcome. In addition, 
we provide further evidence that CTCs can be detected in PDAC patients in the 
portal venous circulation and that the count is increased following tumour 
manipulation. This may affect disease recurrence and survival, but larger studies are 
needed for a definitive answer with regards to outcome. 
 
4.2 Clinicopathological factors which may predict disease recurrence 
 
4.2.1 HYPOTHESIS 
 
In the above study on the no-touch technique, we were unable to significantly prove 
that surgical technique can reduce the recurrence of PDAC.  It was therefore decided 
to plan a retrospective analysis of PDAC patients, in order to identify what 
clinicopathological factors may influence PDAC recurrence after curative resection. 
We hypothesised that there are no clinicopathological differences between patients 
who develop early disease recurrence and those that develop late recurrence or no 
recurrence. 
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4.2.2 RESULTS 
During the period January 2001 to June 2014, 654 patients had pancreatic 
resections at our hepatobiliary centre.  Of these, 178 were for a histopathological 
diagnosis of PDAC, with 168 undergoing curative resections.  The remaining 10 
patients had locally advanced disease or metastatic disease evident intra-operatively 
and had palliative bypasses and/or biopsies.  A further 16 patients had an R2 
resection and were excluded from the analysis.  Of the remaining 152 patients, 68 
(44.74%) had evidence of disease recurrence within 12 months of surgery (Group I) 
and 25 (16.45%) had no evidence of disease recurrence for at least 24 months after 
surgery (Group II).  These 93 patients were included in the analysis.  81 patients had 
a PD and twelve patients had a DP.  Clinicopathological characteristics of the 
patients and tumours are shown in table 7.  There was no 30-day mortality.  
Complications occurred in 30.61% (15 of 49 with available data) with major 
complications (Clavien-Dindo classification 3b-4)357 occurring in 2 patients (4.08%), 
one who required a second operation for wound dehiscence and one who required 
further ITU support following an non-ST segment elevation myocardial infarction 
(NSTEMI), lower respiratory tract infection (LRTI) and upper gastrointestinal bleed 
from a gastric ulcer.  
 
In univariate analysis, factors associated with early recurrence compared to no or 
late recurrence were: resection margin status (p=0.000); medial resection margin 
status (p=0.000), posterior resection margin status (p=0.032), tumour size (p=0.002); 
T-stage (p=0.014); N-stage (p=0.002); and the presence of lymphovascular invasion 
(p=0.018).  No differences between the two groups were found for: type of operation 
(PD or DP); age; sex; tumour differentiation; lymph node ratio; presence of perineural 
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invasion; pre-operative levels of CA 19-9, CRP or bilirubin; morbidity; or the use of 
adjuvant therapies. (Table 7).  
 
Characteristic All patients (n=93) Group I (n=68) Group II (n=25) p value 
Median age   
years (range) 
 
66.66 
(40.71-82.82) 
66.18  
(40.71-82.82) 
67.81  
(49.63-75.36) 
0.697 
Sex 
M:F (%) 
52:41  
(56:44) 
35:33 
(51:49) 
17:8  
(68:32) 
0.168 
Median preoperative  
CA 19-9  
Kunits/L, (range) 
(n=54) 
87.00  
(1-32,876) 
73.00 
(1-32,876) 
198.00 
(1-10,195) 
0.347 
Preoperative CA 19-9 
<37:>37 (%) 
(n=54) 
37:17 
(69:31) 
28:9 
(76:24) 
9:8 
(53:47) 
0.121 
Median preoperative 
bilirubin 
umol/L (range) 
(n=89) 
18 
(2-494) 
18 
(3-248) 
17 
(2-494) 
0.877 
Preoperative bilirubin 
<22:>22 (%) 
(n=89) 
52:37 
(58:42) 
39:27 
(59:41) 
13:10 
(57:43) 
1.000 
Median preoperative CRP 
mg/L (range) 
(n=89) 
6 
(1-141) 
6 
(1-141) 
6 
(1-141) 
0.854 
Preoperative CRP 
<20:>20 
(n=89) 
66:23 
(74:26) 
48:18 
(73:27) 
18:5 
(78:22) 
0.783 
Type of operation 
PD:DP (%) 
81:12 
(87:13) 
58:10 
(85:15) 
23:2 
(92:8) 
0.503 
Morbidity 
no:yes (%) 
(n=49) 
15:34 
(31:69) 
11:24 
(31:69) 
4:10 
(29:71) 
1.000 
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Differentiation 
poor:moderate-to-
poor:moderate:well (%) 
55:10:27:1  
(59: 11: 29:1) 
40:9:18:1 
(59: 13: 26: 1) 
15:1:9:0 
(60: 4: 36: 0) 
0.495 
Resection margin status 
R0:R1 (%) 
45: 48 
(48:52) 
25:43 
(37: 63) 
20:5 
(80:20) 
0.000 
Medial resection margin 
status 
R0:R1 (%) 
57:36 
(61:39) 
33:35 
(49:51) 
24:1 
(96:4) 
0.000 
Anterior resection margin 
status 
R0:R1 (%) 
81:12 
(87:13) 
59:9 
(87:13) 
22:3 
(88:12) 
1.00 
Posterior resection margin 
status 
R0:R1 (%) 
81:12 
(87:13) 
56:12 
(82:18) 
25:0 
(100:0) 
0.032 
Pancreatic resection margin 
status 
R0:R1 (%) 
86:7 
(92:8) 
65:3 
(96:4) 
21:4 
(84:16) 
0.081 
Median tumour size 
cm (range) 
2.8 (0.8-6.5) 3.0 (0.8-6.5) 2.2 (0.9-4.5) 0.002 
T-stage 
1:2:3:4 (%) 
3:8:63:19 
(3:9:68:20) 
3:2:47:16 
(4:3:69:24) 
0:6:16:3 
(0:24:64:12) 
0.014 
N-stage 
N0:N1 (%) 
22:71 
(24:76) 
10:58 
(15:85) 
12:13 
(48:52) 
0.002 
Lymph node ratio 
<0.2: >0.2 (%) 
(n=50) 
21:29 
(42:58) 
18:24 
(43:57) 
3:5 
(38:63) 
1.000 
Perineural invasion 
absent:present (%) 
20:73 
(22:78) 
13:55 
(19:81) 
7:18 
(28:72) 
0.398 
Lymphovascular invasion 
absent:present (%) 
21:72 
(23:77) 
11:57 
(16:84) 
10:15 
(40:60)0.018 
0.018 
Adjuvant chemotherapy 
no:yes (%) 
14:79 
(15:85) 
12:56 
(18:82) 
2:23 
(8:92) 
0.338 
Mortality 
no:yes (%) 
14:79 
(15:85) 
3:65 
(4:96) 
11:14 
(44:56) 
0.000 
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Table 7:  Clinicopathological characteristics of patients in Group I (recurrence within 12 months) and Group II (no 
recurrence for at least 24 months) and p-value results of univariate analysis.  Comparisons were made using Fisher’s 
exact test for categorical data and the Wilcoxon signed rank test for continuous data.  All tests were two-sided. 
 
In multivariate analysis (Table 8), only medial resection margin status was 
associated with early recurrence. (p=0.030, HR 0.031, 95%CI 0.001 – 0.717). 
Mean follow-up to date of death or to final follow-up for patients still alive was 24.8 
months (range 1.5 – 108.1).  By definition all the early recurrence group had disease 
recurrence.  Further, 9 patients (36%) of the no recurrence group, developed disease 
recurrence after 24 months.  Three patients (4.41%) were alive from the early 
recurrence group and 11 patients (44%) were alive from the no recurrence group. 
Overall survival is shown in table 9.  Overall median survival was 9.8 months (95% 
CI 9.0 – 10.6) for Group I which was significantly worse than the 56.1 months (95% 
CI 34.4 – 77.8) for Group II (p=0.000) (Table 9 and Figure 7).  The 1-, 3- and 5-yr 
survival rates of patients with early recurrence was 36%, 0% and 0% compared to 
100%, 74% and 40% for patients without recurrence for at least 24 months.  A cox-
regression analysis showed this difference in survival was significant independent of 
a positive medial resection margin.  P-value remained 0.000 (HR 0.018, 95% CI 
0.004-0.080). 
 
Characteristic p-value 
univariate 
analysis 
p-value 
multivariate 
analysis 
HR 95% CI for HR 
Resection margin status 0.000 0.347 3.787 0.237 – 60.615 
Medial resection margin 
status 
0.000 0.030 
 
0.031 
 
0.001-0.717 
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Posterior resection 
margin status 
0.032 0.998 
 
0.000 
 
0.000 
 
 
Pancreatic resection 
margin status 
0.081 0.100 12.415 0.619-249.415 
Tumour size 0.002 0.179 1.661 0.792-3.482 
T-stage 0.014 0.666 0.808 0.308-2.124 
N-stage 0.002 0.212 2.349 0.614-8.977 
Lymphovascular 
invasion 
0.018 0.178 2.732 0.632-11.808 
Table 8: Multivariate analysis of clinicopathological factors that were significantly different between each group on 
univariate analysis.  HR = Hazard ratio.  CI = Confidence interval. 
 
Group Median Survival, 
months 
95% CI p-value 
I  
(n=68) 
9.8 9.0 – 10.6  
0.000 
II  
(n=25) 
56.1 34.4 – 77.8 
Overall  
(n=93) 
13.8 9.6 – 18.0  
Table 9: Survival for patients in Group I (disease recurrence within 12 months) and Group II (no disease recurrence 
for at least 24 months).  Comparison of survival distributions made with the log rank (Mantel-Cox) significance test. 
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Figure 7: Kaplan Meier survival curve comparing Group I (recurrence, blue) and Group II (no recurrence, green). 
 
4.2.3 DISCUSSION 
Over a thirteen year period, our centre performed 168 curative resections for 
pancreatic ductal adenocarcinoma.  Forty-five per cent developed disease 
recurrence within 12 months and 16 % did not develop disease recurrence for at 
least two years.  It was of interest to compare these two groups to try to identify any 
clinicopathological factors that may predict early disease recurrence compared to no 
or late disease recurrence.  These factors would be of prognostic value.   
 
We had no 30 day mortality and a morbidity of 31% with major morbidity in 4%.  
This morbidity is comparable to the US National Surgical Quality Improvement 
Project data358.  Although a number of factors were found to be associated with 
early recurrence on univariate analysis, only a positive medial resection margin was 
associated with early disease recurrence on multivariate analysis.  Those who 
developed disease recurrence within 12 months, unsurprisingly, had a significantly 
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poorer overall survival with a median of 9.8 months compared to 56.1 months in 
those who had at least two years with no disease recurrence.  Therefore, a positive 
medial resection margin is a prognostic indicator and predicts early disease 
recurrence and poor overall survival. 
 
The medial resection margin faces the superior mesenteric vein (SMV) and has a 
shallow groove-like shape and a fairly smooth surface. To the left is a relatively small 
area of rougher texture that faces the superior mesenteric artery (SMA) and joins by 
an acute angle the slightly fibrous but smooth posterior surface of the pancreatic 
head, which overlies the aortocaval groove 359 (Figure 8).  Several retrospective 
trials have previously identified resection margin status as an independent prognostic 
factor in PDAC patients 160, 360, 361 362 363 364.  In the European Study Group for 
Pancreatic Cancer-1 (ESPAC-1) study, which involved 541 PDAC patients and is the 
largest randomized trial in pancreatic cancer patients, those with an R1 resection 
status had a median survival of 10.9 months versus 16.9 months for patients with R0 
margins 365.  Although, resection margin status was only a significant independent 
prognostic factor when tumour grade and lymph node involvement were both absent 
from the model.  Further, other retrospective studies have failed to identify resection 
margin status as a prognostic factor366 including an American study of 360 
consecutive pancreatic cancer patients 367.  However, few authors have clarified 
which margins were R0 or R1.  Whilst we found overall resection margin status to be 
significant on univariate analysis, this association dissipated on a multivariate 
regression analysis when taking into account the four separate resection margins.  
This is in agreement with Zhang et al. who demonstrated that an R0 medial margin 
was an independent prognostic factor (P = 0.002, HR = 0.381; 95% CI 0.207-0.701) 
156.  
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A positive resection margin may predict a more biologically aggressive tumour.  
Despite macroscopic tumour clearance, a microscopic invasion of the tumour to 
within 1mm of the resection margin implies that some tumour cells have remained at 
the resection bed in the patient.  As the medial resection margin is in close proximity 
to the SMV and SMA, our results may suggest that these microscopic tumour cells 
may enter the systemic circulation to enable metastatic development.  
 
The results of this study would suggest that by improving medial resection margin 
status, we can prolong disease-free and overall survival in PDAC patients 
undergoing curative resections.  By performing portal venous resection and/or SMV 
resection at the time of pancreaticoduodenectomy, it may be possible to reduce R1 
resection rates.  Indeed, in a recent study of 359 PDAC patients, the 131 patients 
who had additional venous resection had significantly more R0 resections (p=0.02) 
368.  By pooling results from studies reporting resection margin status after PD,156, 198-
204 a positive medial resection margin was reported in 38.2% of 701 patients (Table 
10).  A positive medial resection margin varied in these studies from 22.4% - 51.4%.  
Surgical technique and patients selection likely explains this heterogeneity. However, 
following PD with PV/SMV resection, the medial resection margin is only positive in 
16% of patients 205.  Others have suggested completely excising the mesopancreas 
during pancreaticoduodenectomy.  The mesopancreas is defined as the soft tissue 
between the pancreatic head and SMA369.  It includes nerves, vessels and 
lymphatics.  A total mesopancreas excision leads to a significantly increased rate of 
R0 resections370 and is facilitated by using the posterior or artery-first approach371.  
 
This study was limited by its retrospective nature.  Further, it looks at differences 
between two distinct groups of patients .  We can therefore only conclude that those 
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with a positive medial resection margin are more likely to develop disease recurrence 
within 12 months than to have a disease-free survival of at least two years. 
 
 
 
Figure 8: A head of pancreas resection with the superior mesenteric vein (SMV) and superior mesenteric artery 
(SMA) margins shown.  These margins contribute to the medial resection margin.  From The Royal College of 
Pathologists of Australasia (http://www.rcpa.edu.au). 
 
 
Author, year Total no. of  positive 
(R1/R2) resections 
Positive pancreatic 
transection margin  
Positive anterior 
transection margin  
 
Positive posterior 
transection margin  
 
Positive medial 
transection margin  
 
John, 
2013198 
52/70 (74.3%) 2/70 (2.9%) 21/70 (30%) 32/70 (45.7%) 33/70 (47.1%) 
Zhang, 
2012156 
48/84 (57.1%) 3/84 (3.6%) 26/84 (31.0%) 36/84 (42.9%) 25/84 (29.8%) 
Jamieson, 
2010 199 
109/148 (73.6%) 15/148 (10.1%) 40/148 (27.0%) 48/148 (32.4%) 50/148 (33.8%) 
Menon, 2009 
200 
22/27 (81.5%) 3/27 (11.1%) 3/27 (11.1%) 13/27 (48.1%) 12/27 (44.4%) 
Campbell, 
2009201 
128/168 (76.2%) 38/168 (22.6%) 6/168 (3.6%) 69/168 (41.1%) 64/168 (38.1%) 
Fusai, 
2008202 
40/67 (59.7%) 4/67 (6.0%) 7/67 (10.4%) 18/67 (26.9%) 15/67 (22.4%) 
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Table 10: Studies reporting R1 status for each resection margin after pancreaticoduodenectomy and pooled results. 
 
 
4.3 Are disease recurrence rates affected by genetic and epigenetic changes 
and can these be detected in the peripheral circulation? 
 
4.3.1 HYPOTHESES 
 
When analysing clinicopathological factors, which affect disease recurrence in PDAC, 
we only identified a positive medial resection margin as being an independent 
predictor of recurrence.  We therefore thought it was of interest to investigate if other 
tumour factors, such as genetic mutational differences could also be responsible for 
PDAC recurrence.  Further, with the results of our literature review suggesting that 
biomarkers may also influence survival, we planned an investigation to identify these 
biomarkers as potential indicators of recurrence. 
 
We hypothesised that: 
1) DNA mutations can be detected in pancreatic tumour tissue and differences can 
be seen between patients with short disease-free survival and those with long disese 
free survival. 
 
2) These DNA mutations can also be detected in the peripheral circulation 
 
Esposito, 
2008 203 
84/111 (75.7%) 3/111 (2.7%) 8/111 (7.2%) 39/111 (35.1%) 57/111 (51.4%) 
Verbeke, 
2006204 
22/26 (84.6%) 2/26 (7.7%) 4/26 (15.4%) 14/26 (53.8%) 12/26 (46.2%) 
TOTAL 505/701 (72.0%) 70/701 
(10.0%) 
115/701 (16.4%) 269/701 (38.4%) 268/701 (38.2%) 
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3) Other circulating biomarkers including circulating tumour cells and circulating 
miRNA can be used as prognostic markers 
 
4.3.2 RESULTS OF ION TORRENT SEQUENCING ON TUMOUR TISSUE 
 
Ion Torrent sequencing: 
As discussed above, 152 patients underwent curative resections for PDAC from 
January 2001 to June 2014.  68 (44.74%) had evidence of disease recurrence within 
12 months of surgery (Group I) and 25 (16.45%) had no evidence of disease 
recurrence for at least 24 months after surgery (Group II).  The FFPE blocks 
identifying the tumour and the corresponding H&E slides were retrieved for 34 
patients (21 in Group I and 13 in Group II).  Following microdissection of the cut 
FFPE blocks, a mean of 18.3 +/- 14.7 ng/μl of DNA was extracted from each tumour 
sample. 
 
Technical performance of the Ion Ampliseq Cancer Hotspot Panel v2:  DNA 
sequencing was carried out using the ion torrent next generation sequencer (Life 
Technologies) as detailed in Chapter 2.  All samples were processed once with an 
81% success rate.  Samples with poor sequence reads were processed a second 
time.  Successful results were generated in 18 patients from Group I and 11 patients 
from Group II.  Mutations in 34 loci of 12 oncogenes and tumour suppressor genes 
were identified as well as 382 single nucleotide polymorphisms (SNPs).  The mean 
read length was 103bp with a mean of 197,452 reads per sample. 
 
Summary of gene mutations:  All samples identified at least 1 mutated oncogene or 
tumour suppressor gene.  11 samples had one mutation, 7 had two mutations, 5 had 
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three mutations, 2 had 4 mutations and one sample had 5 identified mutations.  
Table 11 summarises the mutations found in each sample.   
 
KRAS mutations:  17/18 (94%) of group I samples contained a KRAS point mutation.  
Of these: 15/17 (88%) were a missense substitution at location 25398284 on 
chromosome 12 substituting guanine for adenine in 12 samples (corresponding to a 
COSMIC mutation ID of COSM521) and guanine for thymine in 5 samples 
(corresponding to a COSMIC mutation ID of COSM520); one mutation was at 
location 25398285 substituting guanine for cytosine (corresponding to a COSMIC 
mutation ID of COSM518); and one mutation was at location 25380275 substituting 
adenine for thymine.  The mean frequency of the mutation found in each sample was 
16.93% (SD 11.04).  This compares to 11/11 (100%) of group II samples, which 
contained a KRAS point mutation (p=0.13).  These were on chromosome 12, with a 
mutation ID of COSM521 in 5 samples (p=0.4513), COSM520 in 3 samples 
(p=0.6784) and COSM518 in 3 samples (p=0.535).  The mean frequency of the 
mutation found in each sample was 7.55% (SD 5.76) p = 0.0078.  See Table 12 and 
Figure 9. 
 
TP53 mutations:  In Group I, 8/18 (44%) had TP53 mutations in 7 different locations 
of chromosome 17, all missense substitutions.   In Group II, 3/11 (27%) had TP53 
mutations (p=0.86) in 3 different locations on chromosome 17.  The mean frequency 
of the mutation found in each sample was 14.3% (SD 9.81) in Group I and 9.12% 
(SD 10.94) in Group II (p=0.23). Table 12 and Figure 9. 
 
CDKN2A mutations:  In group I, 2/18 (11%) had CDKN2A mutations compared to 
0/11 (0%) in Group II (p=0.25).  Both mutations were missense substitutions of 
thymine for cytosine on chromosome 12.  Table 12. 
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SMAD4 mutations:  In group I, 2/18 (11%) had SMAD4 mutations compared to 0/11 
(0%) in Group II (p=0.25).  Both mutations were missense substitutions  on 
chromosome 18.  Table 12. 
 
Multiple mutations:  Two or more mutations were seen in 11/18 (61%) of samples 
from Group I with 3/18 (17%) having three or more.  In Group II, 5/11 (48%) (p=0.41) 
and 1/11 (9%) (p=0.57) had two or more and three or more mutations respectively.  
Interestingly, 11/18 (61%) patients in group I, compared to only 3/11 (27%) patients 
in group II (p=0.12) had a KRAS mutation and a mutation in either p53, CDKN2A or 
SMAD4.  Table 12.  
 
These results show that patients with a higher frequency of KRAS mutation in the 
tumour sample, i.e., more of the tumour DNA contains the mutated KRAS gene, are 
significantly more likely to develop disease recurrence within 12 months than have at 
least 2 years without disease recurrence.  On regression analysis, taking into 
consideration a positive medial resection margin, also found to significantly differ 
between the two groups, both factors retain their significance (high frequency of 
KRAS mutation: p=0.002 and positive medial resection margin: p=0.022). 
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Group Sample Mutated Gene Chromosome Position Frequency of 
mutation (%)  
1 1 KRAS 
TP53 
12 
17 
25398284 
 
7578275 
8.8 
9.7 
1 2 KRAS 
CDH1 
TP53 
12 
16 
17 
25398284 
 
68846147 
 
7578263 
7.1 
50.4 
11 
1 3 KRAS 12 25398284 6.9 
 4 JAK2 
CDKN2A 
KRAS 
STK11 
9 
9 
12 
19 
5073770 
 
21971028 
 
25398284 
 
1223125 
7.9 
37 
12 
53.9 
1 5 CDKN2A 
KRAS 
TP53 
9 
12 
17 
21971186 
 
25398284 
 
7578535 
10.1 
5.6 
8 
1 6 KRAS 
TP53 
12 
17 
25398284 
 
7577548 
 
16 
9.8 
1 7 KRAS 
TP53 
SMAD4 
12 
17 
18 
25398284 
 
7573996 
 
48591896 
10.5 
5.2 
4.8 
1 8 KRAS 
TP53 
12 
17 
25398284 
 
7578555 
16.1 
13.6 
1 9 KRAS 
TP53 
12 
17 
25398284 
 
7578263 
43.2 
35.3 
1 10 ERBB2 17 37880994 13.1 
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1 11 KRAS 12 25398284 7.3 
1 12 PIK3CA 
CDKN2A 
CDKN2A 
KRAS 
SMAD4 
3 
9 
9 
12 
18 
178936093 
 
21971120 
 
21971142 
 
25380275 
 
48591904 
30.2 
40 
34.6 
37.6 
61.9 
1 13 PTEN 
PTEN 
KRAS 
10 
10 
12 
89692883 
 
89720862 
 
25398284 
13.5 
12.5 
23.1 
1 14 KRAS 12 25398284 17.5 
1 15 KRAS 12 25398284 20.5 
1 16 KRAS 12 25398284 7.1 
1 17 KRAS 12 25398285 27.3 
1 18 PTEN 
KRAS 
TP53 
SMAD4 
10 
12 
17 
18 
89692905 
 
25398284 
 
7577542 
 
48591918 
14.8 
21.1 
21.9 
20.3 
2 1 TP53 
KRAS 
17 
12 
7577121 
 
25398285 
2.6 
1.4 
2 2 KRAS 12 25398284 13.2 
2 3 KRAS 
TP53 
12 
17 
25398284 
 
7578208 
13.3 
21.8 
2 4 KRAS 
GNAS 
12 
20 
25398285 
 
57484420 
5.5 
4.7 
2 5 APC 5 112175240 3.6 
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Table 11: Mutations found in each sample. 
 
 
 
 
 KRAS 
mutation 
(%) 
Mean 
frequency of 
KRAS 
mutation, % 
TP53 
mutation 
(%) 
Mean 
frequency of 
TP53 
mutation, % 
CDKN2A 
mutation 
(%) 
SMAD4 
mutation 
(%) 
Two or 
more 
mutations  
Three or 
more 
mutations  
Group 
I 
(n=18) 
17 (94) 16.93 8 (44) 14.30 2 (11) 2 (11) 11 (61) 3 (17) 
Group 
II 
(n=11) 
10 (91) 7.55 3 (27) 9.12 0 (0) 0 (0) 5 (48) 1 (9) 
p-
value 
0.13 0.0078 0.86 0.23 0.25 0.25 0.41 0.57 
Table 12:  The number of samples with KRAS, TP53, CDKN2A, SMAD4 and multiple mutations in each group.  The 
mean frequency of KRAS and TP53 mutations per sample is also shown for each group.  P-values calculated using a 
one-tailed student’s t-test for continuous data and chi squared test for categorical data. 
 
KRAS 
TP53 
12 
17 
 
25398284 
 
7577558 
3.1 
13.9 
2 6 KRAS 12 25398284 13.9 
2 7 KRAS 12 25398284 17.8 
2 8 KRAS 12 25398284 3.3 
2 9 KRAS 12 25398284 3.4 
2 10 KRAS 
STK11 
12 
19 
25398284 
 
1223125 
4.3 
37.5 
2 11 KRAS 12 25398284 3.3 
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Figure 9:  Graph showing the mean percentage frequency of KRAS and TP53 mutations in each group. 
 
 
4.3.3 DISCUSSION OF ION TORRENT SEQUENCING ON TUMOUR TISSUE 
 
4.3.3.1 Our Results: 
We performed high-throughput DNA sequencing using the Ion Torrent multigene next 
generation sequencer on FFPE tumour samples from 18 patients with a short 
disease-free survival and 11 patients with a long disease-free survival.  Our goal was 
to identify genetic differences between these two groups in order to identify a 
prognostic indicator.  We were able to perform the analysis with sufficient full-length 
reads and a mean read length of 103bp using 16 samples per chip with a starting 
DNA volume range of 1.65 to 76.5 ng/μl.  The success rate of this technique was 
81%.  We identified that tumour samples from those with a short disease-free 
survival had a higher frequency of KRAS mutation than tumour samples from those 
with long disease-free survivals. 
 
4.3.3.2 Pancreatic cancer sequencing: 
Cancer is the result of an accumulation of genetic damage in key genes and 
signalling pathways resulting in an uncontrolled growth of mutated cells.  Each 
0
2
4
6
8
10
12
14
16
18
Percentage
frequency of
KRAS mutation
(mean)
(p=0.0078)
Percentage
frequency of
TP53 mutation
(mean)
(p=0.23)
Group I (early
recurrence)
Group II (no
recurrence)
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mutation, whether a single point mutation, or a structural rearrangement of 
chromosomes can lead to a change in protein formation and affect a signalling 
pathway.  Combinations of mutations and signalling pathway disruptions may cause 
a functional change with suppression of tumour suppressor genes and/or activation 
of oncogenes and subsequent growth of the carcinoma.  The first whole exome 
sequencing of pancreatic cancer was published by Jones et al. in 200893.   The 
authors designed primers for 219,229 amplicons covering the sequences of protein-
coding exons from 20,735 genes and analysed 24 advanced PDAC tumour samples.  
An average of 48 somatic mutations were identified in each sample.  Further 
analyses found 69 gene sets that were genetically altered in the majority of the 
tumour samples.  31 of which involved 12 core signalling pathways and processes 
that were each altered in 67 to 100% of each tumour examined.  These pathways 
and the cancer-altering genes mutated to affect these pathways and processes are 
summarised in Figure 10.   Biankin et al. 95 later performed further exome 
sequencing of PDAC, analysing 142 early cases of sporadic PDAC tumour samples 
from patients suitable for curative operations.  They supported the high prevalence of 
genetic mutations known to be important in PDAC, observing mutations in 38 of the 
79 genes reported as mutated in more than one sample in the study by Jones et al.  
They defined novel mutations in a total of 1,456 genes, all-be-it commonly in low 
frequencies, confirming the complexity of PDAC tumour biology.  Further, they added 
to the previous knowledge of signalling pathways and processes affected in PDAC 
by identifying gene sets also involved in chromatin modification (EPC1 and ARID2) 
and axon guidance (SLIT2, ROBO2, ROBO1), implicated in cancer cell growth, 
survival, invasion and angiogenesis 372.  The role of DNA damage repair in the 
pathogenesis of PDAC was highlighted as mutations in ATM were identified in 8% of 
the samples.  By evaluating the consequences of these mutated genes and altered 
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pathways, four genes were identified as being of functional significance in PDAC 
including: KRAS; TP53; CDKN2A and SMAD4.   
 
These two landmark studies were paramount in identifying the genetic mutations, 
driver genes and targeted signalling pathways that are involved in PDAC.  Although 
the genes mutated with high prevalence and shown to be functionally important 
(KRAS, TP53, CDKN2A and SMAD4) were confirmed in both studies, there were 
multiple varying mutations found in each.  Further, each tumour sample analysed 
had different mutations in differing frequencies.  It is likely that multiple gene 
mutations can affect the same pathway and multiple aberrant pathways can lead to 
the initiation and progression of PDAC.  One clear difference between the two 
studies was the use of advanced PDAC samples in the first and early PDAC samples 
in the second.  This may therefore suggest that each tumour can develop new 
mutations during its development and growth.  Certainly, during the progression of 
normal pancreatic tissue to PanIN-1a, PanIN-1b, PanIN-2, PanIN-3 and finally PDAC, 
varying genetic alterations are seen144, 373 72, 374 375 75 77.  Early PanIN-1 lesions show 
point mutations in KRAS, GNAS and telomere shortening376.  Later lesions, PanIN-2 
and PanIN-3, exhibit mutations in CDKN2A with TP53 and SMAD4 inactivating 
mutations occurring in PanIN-3 lesions.  Although PanIN2 lesions often contain as 
many mutations as PanIN3 and invasive tumor samples374, suggesting that the 
effects of the mutations are also time dependent. 
 
Survival analyses were not conducted in the reports of genetic sequencing of PDAC 
and thus we were interested to perform a genetic analysis of our patients with short 
and long disease-free survivals to establish whether any differences exist between 
the two groups. 
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Figure 10:  Signalling pathways and processes altered in pancreatic ductal adenocarcinoma (PDAC) and the 
representative altered genes identified by Jones et al. 377 
 
 
4.3.3.3 DNA sequencing techniques: 
Conventional techniques for genomic evaluation and DNA sequencing use 
chemically synthesised oligonucleotides, or primers, which are hybridised to a target 
DNA and then copied by DNA polymerase.  This allows for the precise order of the 
nucleotides in the DNA sample to be determined.  A location-specific primer 
extension strategy for DNA sequencing was established in 1970 by Ray Wu 378.  
More rapid DNA sequencing methods were later developed by Sanger in 1977379 and 
he was able to sequence the first full DNA genome of a bacteriophage380.  Other 
methods for DNA sequencing including a fluorescent labeling technique 381 and a 
Direct-Blotting-Electrophoresis-System 382 enabled the complete DNA sequence of 
various bacterium, viruses and yeasts.  The Sanger technique became the method of 
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choice due to its reliability and an automated machine was developed as the first 
generation of DNA sequencers.  Over time, improved efficiency led to lower costs 
and mass production of the Sanger method, which was used to complete the Human 
Genome Project in April 2003, sequencing 90% of the human genome, with less than 
1 bp error per 100,000 bp of the finished sequence383.  However, the first generation 
techniques have high costs and require a significant amount of time and large DNA 
quantities to assess multiple molecular alterations.  Thus in the last decade there has 
been the development of next-generation sequencing.  These are technologies that 
use multiplex assays to enable the simultaneous analysis of millions of sequences, 
resulting in lower costs in a shorter time period.  Various next-generation sequencers 
have been developed with the most accurate results obtained from the Ion 
Semiconductor technique, pyrosequencing, sequencing by synthesis, sequencing by 
ligation and chain termination (the Sanger technique) 384.  The Ion Semiconductor 
sequencer (Ion Torrent sequencing, Life Technologies) was released by Ion Torrent 
at the end of 2010.  It is based on the detection of hydrogen ions that are released 
during the polymerization of DNA.  The template DNA strand to be sequenced is 
exposed to each nucleotide in turn.  If the template nucleotide is incorporated into the 
DNA molecules by the polymerase, a hydrogen ion is released.  The change in pH is 
detected by a hypersensitive ion sensor. The template DNA base pairs are 
sequentially flooded with each synthetic nucleotide.  If it is not the correct nucleotide 
then no voltage will be detected and if two nucleotides are added a double voltage is 
detected.  It is the first commercial sequencing machine that does not require 
fluorescence and camera scanning leading to higher speeds, low costs and a smaller 
instrument size384.  Further, only 10ng of DNA is required for accurate analysis.  The 
technique has been validated for many solid tumour types with a similar level of 
accuracy to polymerase chain reaction (PCR) and Sanger sequencing252, 385, 386.  At 
our centre, the Ion Torrent semiconductor is established as a next-generation 
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sequencer for DNA from solid tumours and is already used clinically to target 
oncological treatment of small-cell lung cancer, colorectal cancer and lymphoma.  
We therefore decided to use this method of gene sequencing for this study. 
 
4.3.3.4 KRAS mutations and effects: 
The KRAS oncogene encodes a small GTPase protein (RAS) that cycles between 
GTP-bound active and GDP-bound inactive states.  GTPase-activating proteins 
induce hydrolysis of GTP to the inactive form.  The mutations we have identified stop 
the interaction between the GTPase-activating proteins and KRAS leading to its 
persistent activation.  Activation of KRAS stimulates a number of downstream 
signalling pathways and these in turn have a role in cell proliferation, altered 
metabolism, apoptosis suppression, evasion of the immune response and 
metastasis97.  The effector pathways of the activated RAS protein are known to 
include the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, the RAF/MEK/ERK 
pathway and nuclear factor κB (NF-κB) pathway.   
 
(PI3K)/AKT pathway (Figure 11):  The PI3Ks are a kinase family which 
phosphorylate the 3-hydroxyl group of phosphoinositides.  Tyrosine kinases, 
including: epidermal growth factor receptors (EGFRs); platelet derived growth factor 
receptors (PDGF-Rs); and insulin-like growth factor1 receptors (IGF-1), initiate the 
activation of PI3K.  One way of initialising this activation is by phosphorylating RAS 
to its active form.  When activated, these kinases convert their substrates 
phosphatidylinositol 4,5-bisphosphate (PIP2) into PIP3.  PTEN is able to 
dephosphorylate PIP3 back to PIP2. PIP3 in turn enables pyruvate dehydrogenase 
lipoamide kinase isozyme 1 (PDK1) to phosphorylate protein kinase B (Akt), which 
becomes activated.  The mammalian target of rapamycin (mTOR) kinase protein also 
phosphorylates Akt.  This combined activation of Akt activates and inhibits a number 
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of downstream proteins with a resultant effect of: increased protein synthesis and 
growth; increased cell survival; and increased proliferation387. 
 
Figure 11: The PI3K/Akt/mTOR signaling pathway and associated inhibitors.  Tyrosine kinases activate PI3K via 
activation of RAS.  The active kinase generates PIP3 at the lipid membrane. PIP3 facilitates the phosphorylation of 
Akt by PDK1, while the mTOR-rictor complex contributes a second phosphate residue to Akt. As the central effector 
of the PI3K pathway, Akt transmits signal to a host of downstream substrates, thus influencing a variety of key 
cellular functions.  Adapted from ref 387. 
 
RAF/MEK/ERK pathway (Figure 12):  Raf is a serine/threonine kinase and is 
activated by the active form of RAS which binds to Raf-1 leading to its recruitment to 
the cell membrane.  This enables Raf-1 to be phosphorylated and activated by other 
kinases.  Raf-1 then binds ATP and phosphorylates mitogen-activated protein kinase 
(MEK) which in turn phosphorylates extracellular-signal-regulated kinase (ERK).  
ERK has a number of downstream effects leading to the activation of transcription 
factor targets including NF- B, CREB, Ets-1, AP-1 and c-Myc.  These induce the 
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expression of genes important for cell cycle progression and prevention of 
apoptosis388. 
 
 
Figure 12: The RAF/MEK/ERK pathway.  Activated RAS and other kinases phosphorylate Raf which in turn 
activates MEK and ERK.  This results in the activation of transcription factors which cause the expression of genes 
resulting in cell proliferation and the prevention of apoptosis.  Adapted from ref 388. 
 
NF-κB pathway:  NF-κB is a transcription factor controls over 150 genes and several 
biological responses including immune signalling, inflammation, proliferation, 
apoptosis and development.  The five members of this family are usually inactive in 
the cytoplasm by the binding of their inhibitor proteins (IκBs), which prevent NF-κB 
from entering the nucleus.  Activation of the pathway requires phosphorylation of IκB 
by an IκB kinase (IKK), which marks it for ubiquitination and proteasomal degradation, 
thus releasing NF-κB, which translocates to the nucleus 389.  It is widely believed that 
activated RAS can contribute to the activation of this complex pathway. 
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Considering KRAS is the most frequently mutated gene in PDAC and is also one of 
the earliest genetic changes found in low-grade PanINs, it is thought to be an early 
driver mutation for the development of PDAC.  Mice models with endogenous 
overexpression of mutant KRAS on chromosome 12 have been created.  These 
KRASG12D mice developed early and late stage PanINs.  As the mice aged, high 
grade PanINs were observed with increased frequency.  This substantiates KRAS 
mutation as an important initialising event in pancreatic cancer.  Indeed, 7% of these 
mice also developed metastatic PDAC at 6 and 8 months 103.  The low frequency of 
progression of PanIN lesions to PDAC suggests that further genetic mutations are 
required for disease progression.  When the KRASG12D mice models are created with 
inactivating mutations for tumour suppressor genes, including p53, CDKN2A or 
SMAD4, they develop accelerated PanINs and PDAC 112 117 121.  The inactivation of 
different tumour suppressor genes is found to completely alter the type of precursor 
lesion that develops and the state of the malignant disease 390.  Collins et al. 
generated mouse models for inducible KRASG12D allowing for inducible and 
reversible expression of this mutated gene.  During early tumorigenesis, 
precancerous lesions developed with the induction of the mutant KRAS.  Interestingly, 
the inactivation of KRASG12D led to regression of the lesions to barely detectable or 
undetectable on MRI scanning in just 3 weeks 391.   With re-expression of KRAS they 
saw rapid recurrence of the primary tumour mass and metastatic development.  This 
is in agreement with studies on human pancreatic cell lines that require oncogenic 
KRAS for sustained proliferation and survival.  So, continuous oncogenic KRAS 
signalling is essential for tumour progression and maintenance as well as initiation 392.   
 
We detected KRAS mutations in 94% of the tumour samples from Group I (short 
disease-free survival) and 100% of tumour samples from Group II (long disease-free 
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survival).  This is in agreement with other studies and repeatedly reported as the 
most commonly mutated gene in PDAC.  Indeed, the COSMIC database 
(http://www.sanger.ac.uk/genetics/CGP/cosmic/) reports that 82% of the total number 
of PDAC samples in the published literature have a KRAS mutation.  This includes 
various studies and method heterogeneity may explain our higher percentage.  In 
Group I (early recurrence) 71% of samples corresponded to a COSM521 mutation, 
29% corresponded to a COSM520 mutation and 6% had a COSM518 mutation.  
Similarly in Group II (late recurrence), 45% had a COSM521 mutation, 27% had a 
COSM520 mutation and 27% had a COSM518 mutation.  These 3 COSMIC 
mutations are also those most frequently reported in the literature with the COSMIC 
database stating the COSM521 mutation in 42% of KRAS mutated PDAC samples, 
the COSM520 mutation in 40% of samples and the COSM518 mutation in 15% of 
samples.  Notably, the long disease-free survivors had fewer patients with a 
COSM521 mutation and more patients with a COSM518 although this did not reach 
significance.  We also identified that samples containing a higher frequency of KRAS 
mutation were observed in the short disease-free survival group compared to the 
long disease-free survival group. 
 
KRAS mutational status has been associated with shorter disease-free and overall 
survival in patients following pancreatic resection in some studies. 393, 394.  However, 
in agreement with others395, we did not find that KRAS mutations were more common 
in those with a short, compared to a long, disease-free survival likely due to the high 
percentage of patients with KRAS mutations in all PDAC samples and the reported 
necessity for KRAS in tumour development.  A higher frequency of oncogenic KRAS 
was seen in the short disease-free survival group which suggests that more 
aggressive tumours have more DNA with the oncogenic KRAS, which we know is 
 124 
required for the maintenance of PDAC and for the development of metastatic 
disease391.   
 
Although mouse models have not compared specific mutational statuses with tumour 
progression, there is some published literature suggesting that the type of KRAS 
mutation may play a role in disease recurrence and progression.  An analysis of 27 
PDAC tumour samples suggested that those with a COSM521 mutation had worse 
overall survivals than those with other KRAS mutations396.  Although this result did 
not reach significance it is a similar finding to our results and hints towards different 
KRAS mutations having different effects on tumourigenesis and the signalling 
pathways affected.  Indeed, others have reported that overall survival is reduced in 
those with a COSM521 mutation (HR=2.42; 95%CI 1.14–2.67; P = 0.03) 397. 
 
4.3.3.5 TP53 mutations and effects: 
Tumour protein 53 (p53) is a nuclear phosphoprotein and functions as a transcription 
factor.  It is widely regarded as a tumour suppressor gene.  It activates the 
transcription of several genes that carry out the p53 dependent functions in a cell.  
P53 plays a central role in cell cycle regulation, regulation of apoptosis, and DNA 
repair398.  When an upstream event causes DNA damage from a stressor such as: 
ultraviolet light; irradiation; chemical agents; oxidative stress; osmotic shock; 
ribonucleotide depletion; or dysregulated oncogene expression, there is a rapid 
increase in the level of p53 in the cell by prolonging the p53 half life, and an increase 
in its activation as a transcription factor.  The increase is proportional to the extent of 
DNA damage.  The N-terminal domain of p53 contains a large number of 
phosphorylation sites so it is believed that these are targets for protein kinases 
transducing stress signals.  One of the downstream targets of p53 is transcription of 
p21.  P21 binds to cyclin complexes thus inhibiting kinase activity.  Cyclin complexes 
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have an important role in the p16–cyclin D1–cdk4–Rb pathway, which is central to the 
regulation of the G1-to-S phase transition during cell growth.  Thus p53 has a role in 
G1 arrest via the transcription of p21 398.  P53 is also able to initiate apoptosis by 
gene transcription and by direct protein signalling.  Interestingly, p53−/− mice are 
unable to produce the normally observed apoptosis of thymocytes after exposure to 
DNA damaging stimuli399.   
 
In cancer, mutations in p53 result in a loss of normal function allowing the cells to 
escape DNA damage control checkpoints and programmed G1 arrest or cell death, 
thus contributing to genomic instability 114  In pancreatic cancer, the mutated gene is 
seen in late PanINs and therefore, although not an initializing event, likely contributes 
to the development and progression of PDAC.  Indeed, loss of p53 or mutated p53 
permits the growth of KRAS-mutated cells in mice, promoting the progression of 
premalignant lesions to PDAC and driving metastatic development 400.   
 
We identified p53 mutations in 44% of tumour samples from the short disease-free 
survivors and 27% of those from the long disease-free survivors.  This is in 
concordance with the literature where p53 is repeatedly shown to be the second 
most commonly mutated gene in PDAC.  Out of our eleven patients with p53 
mutations, 10 of these were at different locations on chromosome 17.  Again, this is 
in agreement with the COSMIC database where 202 different p53 mutations have 
been identified in 395 samples.  Although the difference in mutational status between 
our two groups did not reach significance in our small sample set, it indicates a trend 
that patients with p53 mutations have worse survival.  As discussed above, they may 
be unable to arrest cell growth in this micrometastatic disease, resulting in earlier 
recurrence of detectable lesions.  Certainly, P53 has been shown to be one of the 
top three upstream regulators of the proteins associated with short-term survival in 
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PDAC 401.  Further, mutant p53 increases chemoresistance to gemcitabine 402 which 
would therefore shorten survival. 
 
4.3.3.6 CDKN2A mutations and effects: 
Cyclin-dependent kinase Inhibitor 2A (CDKN2A) is a tumour suppressor gene which 
codes for several proteins including p16, INK4A and ARF.  P16 is a key regulator of 
the G1-S transition of the cell cycle by inhibiting cyclin dependent kinases such as 
CDK4 and CDK6.  The kinases phosphorylate retinoblastoma protein (pRB) which 
results in progression from G1 phase to S phase114.  Thus its mutation and loss of 
function inhibits cell growth.  CDKN2A mutations usually occur in the later stages of 
the pancreatic tumour progression model403.  Mice with a knock-in KRAS mutation 
and a p16 knock-out show rapid progression of PanIN lesions to PDAC112, 115.  Our 
results identified a CDKN2A mutation in 11% of those with short disease-free 
survivals and in 0% of those with long disease-free survivals although this was not a 
significant finding.  The COSMIC database reports that 23% of all PDAC samples 
reported in the literature have a CDKN2A mutation.  Our results are in agreement 
with previous studies finding a poorer survival in those with a CDKN2A mutation but 
without reaching significance397. 
 
4.3.3.7 SMAD4 mutations and effects: 
Mothers against decapentaplegic homolog 4 (SMAD4) is a tumour suppressor 
protein involved in cell signaling.   It is essential in the SMAD pathway, altering the 
transforming growth factor TGF-β pathway.  In the TGF-β pathway, TGF-β dimers 
bind to and activate transmembrane type II receptors which phosphorylate and 
activate a type I cell surface receptor.  This leads to the activation of SMADS which 
bind to SMAD4.  The SMAD complex can then translocate to the nucleus where it 
interacts with transcriptional activators to regulate gene expression.  Many TGF-β 
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ligands use this pathway and thus SMAD4 is involved in biological functions including, 
of note, apoptosis and the cell cycle.  SMAD4 deficiency inhibits the TGF-β-induced 
cell cycle arrest and migration, contributing to tumour formation 404.  In our study, 
11% of those with short disease-free survivals and 0% of those with long disease-
free survivals had a SMAD4 mutation, suggesting a trend for better survival in those 
without this mutation.  The COSMIC database reports SMAD4 mutations in 21% of 
PDAC samples.  Previous work is in agreement with our results finding that a loss or 
mutation of SMAD4, in tumours from those who had died of PDAC, correlated with 
distant metastases 219.  Further, analysis of SMAD4 on 174 tumour specimens found 
SMAD4 status to be significantly correlated with portal vein invasion, lymph vessel 
invasion, and perineural invasion and was an independent prognostic factor 405. 
 
4.3.3.8 Multiple mutations: 
Considering each driver mutation in PDAC acts through differing pathways, we would 
expect multiple mutations to worsen tumourigenesis and link to survival.  Particularly 
when the mutated KRAS, acting as an oncogene, is in combination with a tumour 
suppressor gene.  Certainly, when mouse models with mutated KRAS are combined 
with loss-of-function alleles of p53 and/or CDKN2A, an acceleration of PDAC growth, 
more genetic instability and a tendency for poorly differentiated tumours is seen 390. 
 
Although we found no significant differences between our two groups in terms of 
number of diver mutations identified, there was a trend towards more mutations in 
the short disease-free survival group.  Indeed, 61% of short disease-free survival 
patients compared to only 27% of long disease-free survival patients had a KRAS 
mutation and a mutation in either p53, CDKN2A or SMAD4.  This is in agreement 
with others who have found poor survivals in patients with concomitant KRAS and 
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CDKN2A mutations397, and the number of driver gene alterations has been found to 
be an independent prognostic factor for overall survival219. 
 
4.3.3.9 Limitations:  
This study is greatly limited by its size.  We had a total of 18 patients in group I and 
11 patients in group II, which falls short of our power calculation target of 14 in each 
group, and puts our data at risk of a type II error.  Further, due to difficulty in 
obtaining the FFPEs and their corresponding slides we were only able to extract 
DNA from one part of the tumour in each sample.  It is well known that PDACs 
exhibit tumour mutational heterogeneity and thus we may have found different results 
if each sample had come from a different part of the PDAC specimen. 
 
4.3.3.10 Conclusions:  
From next-generation gene sequencing of 29 PDAC tumours we found that a high 
frequency of KRAS mutation was more likely to occur in those with short, rather than 
long, disease-free survival and this was an independent prognostic marker.  Further, 
a trend towards worse survival was seen in those with a COSM521 mutation of 
KRAS and a trend towards better survival was seen in those with a COSM518 
mutation of KRAS.  Short disease-free survivors also trended towards having 
multiple mutations, particularly of p53, CKDKN2A, and SMAD4.  Genetic mutational 
analysis could therefore direct personalised therapy and be used to stratify patients 
for more aggressive local or systemic treatment following surgical resection. 
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4.3.4 RESULTS FROM BLOOD SAMPLES:   
 
4.3.4.1 cfDNA sequencing 
Considering patients with a high frequency of KRAS mutation are more likely to 
develop disease recurrence within 12 months than to have at least two years free 
from disease, it is of interest to sequence cell-free DNA from blood samples of these 
patients as a potential prognostic biomarker.  Blood samples from the peripheral 
circulation were collected from a total of sixteen patients (8 in Group I and 8 in Group 
II).  A mean of 63.67 +/- 24.37 ng/μl of DNA was extracted from each sample.  A total 
of 256 SNPs were identified from the total of 16 samples.  A genetic mutation was 
identified in two samples:  an APC gene mutation and an STK11 mutation, the 
location of which corresponded to the tumour sample mutations seen in these 
patients.  No other mutations, specifically no KRAS mutations were identified in any 
samples. 
 
4.3.4.2 Circulating tumour cells (CTCs) analysis:  As cell-free DNA was not identified 
as a biomarker in this study, it was decided to look at alternative prognostic 
biomarkers.  CTC analysis was undertaken from the peripheral circulation blood 
samples in the same sixteen patients (8 in Group I and 8 in Group II).  A median of 0 
CTCs per sample (range 0-2) were found, with a median of 0.5 in Group I and 0 in 
Group II (p=0.33).  Figure 13. 
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Figure 13: CTC analysis for Group I (recurrence within 12 months) and Group II (no recurrence for 24 months).  No 
significant difference found between each group (p=0.33). 
 
 
4.3.4.3 microRNA (miRNA) analysis:  Our group has previously found that a 
combination of miR-21, miR-23a and miR-27a from PDAC tumour samples is 
associated with shorter survival after surgical resection 406.  Therefore, we 
hypothesised that circulating miRNAs may distinguish between our two groups of 
patients and be of potential use as prognostic biomarkers.   
 
Blood from the sixteen patients used above was also analysed for miRNAs using the 
NanoString nCounter system expression assay.  Using a significance value of <0.01, 
five miRNAs were differentially expressed between patients with short disease-free 
survival and those with long disease-free survival:  hsa-miR-548ah-5p; hsa-miR-
550b-3p; hsa-miR-223-3p; hsa-let-7b-5p and hsa-let-7c.  Three were downregulated 
and two upregulated in Group I compared to Group II (Table 13).  These miRNAs 
were entered into the MiRTarBase database (May 2015).  Only one of these 
differentially expressed miRNAs has been found to target genes identified as 
mutated in the genetic sequencing of our PDAC samples, namely hsa-let-7b-5p 
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(target KRAS).  None of these miRNAs have been previously identified as prognostic 
indicators in pancreatic cancer.   
.  
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miRNA Base Mean Log2 Fold Change Adjusted p-value Upregulated/ Downregulated in 
Group I compared to Group II 
PDAC Gene Target 
hsa-miR-548ah-5p 
 42.63822508 -0.712787648 
0.001728 Down-regulated Nil known 
hsa-miR-550b-3p 46.53592309 -0.61247248 0.245326 Down-regulated Nil known 
hsa-miR-223-3p 155.6722423 0.603150078 0.080409 Up-regulated Nil known 
hsa-let-7b-5p 60.40780961 0.607372968 0.085134 Up-regulated KRAS 407 
hsa-let-7c 41.9846227 -0.346058076 0.085134 Down-regulated Nil known 
 
Table 13: The five most differentially expressed circulating microRNAs between Group I and Group II.
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4.3.5 DISCUSSION OF BLOOD RESULTS 
 
4.3.5.1 Gene sequencing of cell-free DNA (cfDNA): 
Genetic sequencing of blood DNA did not reveal any mutations in the four driver 
genes associated with PDAC and seen in the sequencing of the patients’ tumour 
samples.  The mutational analysis of cf-DNA is therefore not a useful prognostic 
marker in patients with resectable PDAC.  The Ion Torrent™ PGM sequencer has 
been used by others to detect mutations in cfDNA of patients with HCC 408, 
methylmalonic acidemia 409, chronic lymphocytic leukemia 253 and breast cancer 410.  
Whilst some concentrated on DNA extraction from plasma, others used whole-blood 
samples, such as in our study.  We had high volumes of DNA extracted from our 
samples and sufficient full-length reads were obtained.  Further, multiple SNPs were 
detected as well as two gene mutations.  Interestingly these gene mutations were in 
a germline STK11 variant and in APC, and both mutations were seen in the 
corresponding tumour analysis.  This suggests that the Ion Torrent performed 
technically well and was able to analyse the DNA mutational status appropriately.  
However, we can report that the genetic mutations identified in the tumour were not 
seen in peripheral blood DNA.  Indeed, both STK11 and APC mutations are known to 
be a familial cause of PDAC suggesting that these two patients had familial 
circulating DNA with these mutation defects, which may have led to the cause of the 
PDAC rather than be resultant from it.  Other studies which have detected mutation 
defects in cfDNA (Table 3) only detected KRAS mutations in the blood of 33-54.5% 
of PDAC patients compared to the 82% of PDAC tumour samples known to show 
KRAS mutations.  Further, the majority of the studies took blood samples from those 
with unresectable disease and thus at a later stage than our patient cohort.  With this 
in mind it is therefore likely that patients who have resectable pancreatic cancer have 
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not yet shed tumour cells with DNA containing the mutational defect into the systemic 
circulation and cfDNA cannot be used as a prognostic marker in these patients. 
 
4.3.5.2 Analysis of circulating tumour cells (CTCs): 
There were no differences seen in the number of CTCs detected in the peripheral 
circulation between the short- and long- disease-free survival patients.  Our finding of 
CTCs in 50% of the total number of patients concurs with the literature where at least 
one CTC has previously been detected in the blood of 43-80% of PDAC patients.267, 
268, 270   Although a shorter progression-free survival has previously been correlated 
with the detection of CTCs, all these studies were conducted in patients with 
unresectable progressive disease undergoing oncological treatment.  In the only 
other study conducted on patients with resectable PDAC, only 25% had detectable 
CTCs and, in agreement with our study, these patients did not have shorter disease-
free or overall survival compared to the CTC-negative patients271.  The detection of 
CTCs however has been linked to survival in other cancers, including metastatic 
breast cancer 260-262, colorectal cancer 263, 264, castrate-resistant prostate cancer 265 
and in small-cell-lung-cancer 266.  In each of these cases, which differs from all 
reports of CTCs in PDAC, large numbers of CTCs are detected.  Indeed, in breast 
cancer, a cut-off of at least 5 CTCs/7.5ml blood is required to enumerate CTC 
reported differences in median progression-free or overall survival, 411 but we only 
detected a maximum of 2 CTCs/7.5ml blood in our patients.  Although the CellSearch 
system is the most commonly used for CTC detection and the only one with FDA 
approval, it may be that PDAC cells have specific characteristics which means they 
are not detected by this method.  Indeed, the CellSearch system assumes that 
cancer cells have epithelial tissue by relying on the detection of cytokeratins 8- 18- 
and 19-, proteins found in the intracytoplasmic cytoskeleton of epithelial tissue.  
However, some cancer cells undergo an epithelial-mesenchymal-transition (EMT), 
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resulting in the downregulation of EpCAM and some cytokeratins343.  EMT signifies 
an aggressive cancer and facilitates cancer invasion, so the known aggressive 
nature of PDAC would suggest that many of its cells undergo an early EMT even in 
those with resectable disease.  An analysis of E-cadherin expression (which is 
expressed in epithelial cells) confirms this theory as 43% of PDAC tumours from 
those with resectable disease had partial or complete loss of E-cadherin 412.   
Pancreatic cancer cell lines harboring KRAS mutations do tend to exhibit EMT 
induction, and the EGFR/Ras pathway correlates with the genesis and promotion of 
EMT-induced tumor-initiating cells 413.  Moreover, EMT status is associated with poor 
prognosis and adverse clinical outcomes in PDAC 412, and cancer cells with EMT 
possess features that represent resistance to chemotherapy414. 
 
Ultimately, we may be missing the detection of many pancreatic tumour cells, which 
have undergone EMT in keeping with the invasive nature of the disease.  Newer 
technologies for CTC detection in PDAC may be on the horizon, but until these have 
been validated CTCs are unlikely to be of use as prognostic biomarkers in pancreatic 
cancer. 
 
4.3.5.3.1 Analysis of circulating miRNAs: 
miRNAs are small endogenous non-coding RNA molecules around 22 nucleotides in 
length.  This compares to messenger RNAs (mRNA) which are approximately 2000-
5000 base pairs in length.  They function in post transcriptional regulation of gene 
expression and RNA silencing by targeting mRNA for either direct cleavage, 
translational repression or transcript destabilisation415.  The total expression of 
miRNA directly affects the degree to which mRNA targets are altered.  Following 
transcription of DNA, RNA polymerase copies the DNA to form one-stranded mRNA.  
The mRNA is transported from the nucleus to the cytoplasm where it can then be 
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translated by ribosomes and specifies the amino acid sequence of the protein 
products of gene expression.  Considering miRNAs can affect mRNA and resultant 
gene expression, numerous mechanisms of miRNA biogenesis and behaviours have 
come under scrutiny.  The miRNA pathways are extremely complex with thousands 
of miRNAs established and each one thought to target around 400 genes416.  
Disruption of these processes can disrupt the homeostasis of miRNAs, causing them 
to act pathologically, or, pathologically abnormal gene expression may result in 
differential expression of miRNAs.  Compared to RNA, miRNAs are remarkably 
stable and protected from degradation due to their small size417.  Techniques to 
measure their expression have thus been developed and their role in human disease 
has been extensively investigated   Almost all developmental and physiological 
processes are linked to miRNAs and their dysregulation has been linked to many 
diseases including cancer418.  They have been shown to act as both oncogenes and 
tumour suppressors and expression profiling of miRNAs has associated specific 
individual or groups of miRNAs with certain cancers.  The PDAC miRNome has been 
profiled and distinctive miRNA signatures have been shown to be useful in detecting 
pancreatic cancer from FFPE tissue419, blood318, EUS-FNA samples420 and stool 
samples.  Expression profiling has found that pancreas-specific miRNAs are 
dysregulated in PDAC compared to the normal pancreas, chronic pancreatitis and 
other tumours.  Each report in the literature has identified aberrant miRNA 
expression in numerous miRNAs and the majority report unique but differing 
signatures of both up-regulated and down-regulated miRNAs421.  Ma et al. 422 
conducted a robust meta-review of the profiled miRNome and identified a diagnostic 
miRNA signature comprising up-regulated miR-21, miR-23a, miR-31, miR-100, miR-
143, miR-155 and miR-221; and down-regulated miR-148a, miR-217 and miR-375. 
This meta-review found that miR-21 is one of the most frequently up-regulated 
miRNAs in PDAC although it is also dysregulated in many other malignancies. 
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4.3.5.3.2 MiRNAs with prognostic significance: 
A recent meta-analysis423 pooled results of 20 studies analysing 1525 patients with 
PDAC and correlated the tumour miRNA results with survival.  They identified a 
prognostic significance for up-regulated tumoural miR-10b; miR-21; miR-155; miR-
196a/b; miR-203 and miR-222; and down-regulated miR-34a/b.  These were 
independently prognostic for overall survival in PDAC.  miR-21 was the strongest 
predictor of overall survival even when adjusting for other prognostic factors (HR: 
2.66) and when adjusting for adjuvant therapy (HR: 2.72).  However, some of the 
publications pooled contained a mixture of resectable and locally advanced PDACs.  
As those with increasing stage of PDAC have shorter survivals, those patients with 
locally advanced disease may have been driving the miR-21 result. 
 
4.3.5.3.3 Our Findings: 
We identified five circulating miRNAs that were differentially expressed between 
patients with short- and those with long- disease free survivals:  hsa-miR-548ah-5p; 
hsa-miR-550b-3p; hsa-miR-223-3p; hsa-let-7b-5p and hsa-let-7c.  Although none of 
these miRNAs have been previously reported as being of prognostic significance in 
PDAC, the let-7 family is known to target KRAS. 
 
4.3.5.3.4 The let-7 family: 
Lethal-7 (let-7) was first identified as a heterochronic gene in C. elegans in 2000.  
The let-7 mutants failed to exit the cell cycle and the larval cells died 424.  The 3'UTR 
of RAS was later identified as a top-scoring candidate containing let-7 
complementary sites.  They found that let-7 was able to regulate RAS expression425.  
Similar let-7 complementary sequences were also found in the 3'UTR of human RAS 
mRNAs.  There are 12 different members of the let-7 family (let-7a-1, 7a-2, 7a-3, 7b, 
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7c, 7d, 7e, 7f-1, 7f-2, 7g, 7i, and mir-98) expressed in humans.  These all have a 
highly conserved region of nucleotides, important for target recognition and 
suggestive that the members share some targets and functions426.  In human cancer, 
members of the let-7 family are widely reported as tumour suppressor miRNAs with 
down-regulation observed in many cancer types.  In prostate cancer, almost all 
members were down-regulated although in ovarian cancer, only levels of let-7d and 
let-7f were reduced427.  Reduced let-7 expression corresponds to elevated RAS 
expression in small-cell lung cancer428 and increased let-7 expression suppresses 
RAS and abolishes tumorigenesis in non-small-cell lung cancer429 and cell growth in 
a mouse model of breast cancer430.  The mechanism for let-7 down-regulation in 
KRAS driven cancers is thought to be because KRAS up-regulation leads to the 
induction of LIN-28 (a negative regulator of let-7) which thus reduces let-7 
expression431. 
 
In addition, let-7 suppresses growth and cell cycle progression in cancer by 
repressing cell cycle regulators such as cyclins A, D1, D3 and CDK4 and by 
suppressing MYC expression, abolishing MYC-induced cell growth in Burkitt-
lymphoma cells426.  In addition, there are examples of let-7 showing oncogenic 
behavior with the up-regulation of some members seen in high grade transformation 
in lymphoma432 and let-7a targets caspase-3mRNA, an essential protease activated 
during apoptosis in squamous cell carcinoma and hepatocellular carcinoma cell 
lines433. 
 
In PDAC, let-7 has been seen to be up-regulated in normal ductal cells compared to 
PDAC cell-lines and in patient samples, has been shown to be expressed in normal 
pancreatic cells but not in cancerous cells434.  In PDAC cells with mutated KRAS, 
down-regulation of KRAS and MAPK and a strong inhibition of cell proliferation was 
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seen with the introduction of let-7a.  However, mice injected with KRAS-mutant 
PDAC cells over-expressing let-7a failed to exhibit stunted tumour growth434.  In 
human patients, Ali et al. 435, found that let-c and d were down-regulated in PDAC 
FNA samples compared to samples from the normal pancreas.  Further, significantly 
shorter survival after potentially curative resection was seen in lung cancer patients 
with reduced let-7 expression (P = 0.0003) 428.  This supports our finding of down-
regulated let-7c in the short disease-free survival group and a tumour suppressor 
role of let-7c in PDAC.  In contrast, Henry et al. 436 found let-7b to be up-regulated in 
the aspirate of cancerous cystic tumours, which supports our finding of up-regulated 
let-7b in the short disease-free survival group and an oncogenic role of let-7b in 
PDAC. 
 
4.3.5.3.5 miR-548: 
miR-548 is from a larger human gene family located on almost all human 
chromosomes, with 69 members documented 437.  There is little published research 
regarding its influence on cancer, which may reflect its low expression levels 
compared to other miRNAs and thus difficulty in detecting expression with some 
miRNA expression profiling methods available.  However, there are more than 3,500 
hsa-mir-548 target genes and analysis of their expression profiles and functional 
affinities suggests that they have cancer-related regulatory roles 438.  In fact, some 
members of this family have been shown to be important as tumour suppressors.  
Indeed, one member has been identified in the fourth intron of the human FHIT gene 
on a xenograft mouse model injected with tumour cells and on human tissue analysis 
of cervical, brain, colon, melanoma and lung cancers.  Increased expression of this 
miRNA was able to inhibit tumour cell growth439.  Although FHIT was not analysed by 
the ion torrent package used in our gene sequencing study, previous work has 
identified that the tumour suppressor gene FHIT is expressed in pancreatic ductal 
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cells and aberrant in PDAC 440, 441 442 443.  The nanostring technique for miRNA 
analysis is particularly advantageous in identifying miRNAs with low expression 
profiles.  We found that a member of the miR-548 family was down-regulated in the 
short disease-free survival patients and this may be due to its regulatory influence on 
FHIT, which is aberrantly expressed in PDAC. 
 
4.3.5.3.6 miR-550: 
According to miRBase, hsa-miR-550 is located in chromosomal region 7p14, and two 
members of the hsa-miR-550 family have been identified: hsa-miR-550a and hsa-
miR-550b.  miR-550 has been shown to regulate CPEB4 444.  In PDAC, the 
expression of CPEB4 is up-regulated, driving the growth and invasion of cancer cells 
445.  miR-550 has previously been shown to be dysregulated in non-small-cell-lung 
cancers 446, MALT lymphomas 447 and hepatocellular carcinoma (HCC) 444.  Further, 
in childhood acute lymphoblastic leukaemia, miR-550 was down-regulated in patients 
with early relapse 448 and in HCC, miR-550a markedly promoted cell migration and 
invasion.   More specifically, miR-550b-3p, which was differentially expressed in our 
study, has been found to be dysregulated in cervical cancer 449.  Whilst not previously 
reported as dysregulated in PDAC, these studies confirm an important role for miR-
550 in cancer and as a potential prognostic indicator, which may be via its regulation 
of CPEB4.   
 
4.3.5.3.7 miR-223: 
miR-223 comprises a family of miRNAs which are known to regulate a number of 
biological processes with roles in granulopoiesis, haematopoietic differentiation, 
immune cell function and activation, inflammatory disorders and infection.  As well as 
these, it is well known to be dysregulated in cancer, particularly haematological 
malignancies450.  There is also increasing evidence for miR-223 in solid cancers.  
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Certainly HeLa cells injected into mice show suppressed proliferation and tumour 
growth when the cells are overexpressed with miR-223451.  This was caused by 
reduced expression of the miR-223 target IGF1R and downstream 
Akt/mTOR/p70S6K signaling.  miR-223 may also influence cell proliferation by 
targeting the transcription factor FOXO1452.  In HCC, down-regulation of miR-223 
causes up-regulation of STMN1, a regulatory protein frequently overexpressed in 
cancer453.  Of note, an elevated STMN1 expression has been associated with tumour 
progression and poor prognosis in PDAC 454.  Further, a p53 mutation associated 
with poor prognosis represses miR-223 in breast and colon cancer cell lines455.  
Interestingly, there is also evidence of its up-regulation, as seen in our results, 
potentiating metastatic disease.  It is over expressed in metastatic gastric cancer 
cells456 and in recurrent ovarian cancer, compared to primary tumours suggesting a 
metastatic signature457.  In PDAC, miR-223 has been identified as strongly up-
regulated in PDAC tissue compared to normal pancreas419, 458, 459.  Therefore, up-
regulation of miR-223 is seen in PDAC and our results show this may be of 
prognostic significance.  However, the mechanisms of this action remain poorly 
understood. 
  
4.3.5.4 Limitations: 
The blood samples for the cfDNA, CTCs and circulating miRNAs were obtained from 
8 short disease-free survival patients and 8 long disease-free survival patients. This 
was therefore a limited study in terms of sample size and subject to the effect small 
sample sizes have on extreme outcomes. Furthermore, we did not validate our 
miRNA results using alternative methods of miRNA detection (e.g. Quantitative Real 
Time Reverse Transcription PCR). In addition, independent groups of patients would 
be required to fully validate these findings, including a large cohort of pre-operative 
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PDAC patients. In the near future, we intend to assess the prognostic ability of these 
miRNAs in a prospective manner. 
 
4.3.5.5 Conclusions: 
From these results we can conclude that neither CTCs, detected using the 
CellSearch System, nor gene mutational analysis of cfDNA are likely to be of benefit 
as prognostic biomarkers in PDAC.  We have identified five circulating miRNAs (hsa-
miR-548ah-5p; hsa-miR-550b-3p; hsa-miR-223-3p; hsa-let-7b-5p and hsa-let-7c) that 
may be of prognostic value.  Prognostic miRNA signatures for PDAC have differed 
with each publication thus it is clear that large scale multi-centred prospective clinical 
studies should be carried out to determine the most effective combination of miRNAs 
for predicting survival outcomes in PDAC.  There is a lack of blood-based miRNA 
research so until larger analyses are undertaken, we cannot reliably predict 
prognosis in PDAC and we are far from using circulating miRNAs as a biomarker.  
Once we have these large scale results, it is possible that a miRNA signature could 
be used as a PDAC prognostic biomarker thus impacting therapeutic aggressiveness 
and allowing both clinician-selection and patient-choice as to the benefit of surgical 
resection and chemotherapy regimes.  
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CHAPTER 5:  
Summary of findings and future perspective 
 
Pancreatic ductal adenocarcinoma (PDAC) has one of the poorest survivals of any 
solid cancer.  Despite major advances in genetics; our knowledge of tumourigenesis; 
oncological treatment and surgical technique, the 5-year survival rate has shown 
almost no improvement over the last two decades.  This is in contrast to almost all 
other cancers of the human body.  Most pancreatic cancers will not be operable at 
initial diagnosis and the treatment is for prolonging life by a few months and/or for 
palliation of symptoms.  Those with an early diagnosis of a small operable tumour 
who undergo pancreatic resection have a significantly improved overall survival.  
However, even 95% of these patients eventually develop disease recurrence and die 
within 5 years.   It is not currently possible to predict prognosis in these patients in 
order to identify short and long-term survivors, which could lead to a more tailored 
and personalised management approach. 
 
This thesis investigated potential predictors of disease recurrence in patients post 
pancreatic resection for PDAC.  A literature review identified three promising 
prospective biomarkers: circulating tumour cells (CTCs); cell-free DNA and 
circulating microRNAs.  We used CTCs to determine whether different surgical 
approaches could influence disease recurrence rates, specifically comparing the 
standard pancreaticoduodenectomy (PD) and the no-touch PD technique.  Although 
the number of CTCs in the portal vein was significantly more following the standard 
PD compared to the no-touch PD, the difference in disease-free and overall survival 
did not reach significance.  This suggested that an increase in CTCs does not 
necessarily lead to disease recurrence and changing surgical technique may not 
influence prognostic outcome.  We therefore aimed to find clinicopathological factors 
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which could predict disease recurrence in PDAC patients.  Two groups of patients 
were compared:  short disease-free survivors (recurrence <12 months post-
operatively) and long disease-free survivors (no recurrence for >24 months).  
Multivariate analysis identified a positive medial resection margin as the only 
independent prognostic indicator in patients following curative surgical resection.  
Although survival is much better for these patients, those with R0 resection are still 
likely to develop disease recurrence.  We therefore hypothesised that there may be 
genetic differences between these two groups of patients and that these genetic 
alterations could predict early disease recurrence.  From genetic sequencing of 
tumour tissue we were able to identify mutations in the key driver genes known to 
play a role in the pathogenesis of PDAC.  Similar mutations were seen in the short- 
and long- disease free survivors however, the early recurrence group had 
significantly more DNA with mutant KRAS, that is, a higher frequency of KRAS 
mutation.  The early recurrence group also trended towards having a COSM521 
mutation of KRAS and multiple mutations, particularly of p53, CKDKN2A, and 
SMAD4.  The late recurrence group trended towards having a COSM518 mutation of 
KRAS.  These genetic differences between the two groups could be analysed for 
each patient to predict prognosis.  We also wanted to identify whether the same 
mutations could be seen from the sequencing of cell-free DNA from peripheral blood 
samples, which could lead to a prognostic biomarker.  However, the mutations seen 
in the tumour tissue could not be identified in the peripheral circulation.  This led us 
to look for other prognostic biomarkers in the peripheral circulation including CTCs 
and microRNAs.  Although the numbers of CTCs did not appear to differ between the 
two groups, we did find five microRNAs whose expression was significantly different 
between the two groups: hsa-miR-548ah-5p; hsa-miR-550b-3p; hsa-miR-223-3p; 
hsa-let-7b-5p and hsa-let-7c.   
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In summary, our research has highlighted the importance of medial resection margin 
status; frequency of KRAS mutation; and the expression of five circulating 
microRNAs, in predicting disease recurrence in PDAC.  However, there were 
limitations to all the research conducted, particularly in view of the retrospective 
nature of patient identification and of small sample sizes.  The next stage of this 
project should involve prospective validation of our findings.  All PDAC patients 
suitable for resection should have blood collected and stored for the analysis of these 
five microRNAs and their expression should be confirmed by at least two methods.  
The histology will report on medial resection margin status and the tumour tissue 
DNA should be analysed for KRAS frequency.  Should these findings be reproduced 
in this prospective manner then a multi-centred approach should be taken in order to 
further validate our work.  If our results can be validated and replicated then we may 
find these factors are reliable predictors of disease recurrence.  This could lead to 
personalised treatment such that those with poorer disease-free survival prediction 
may undergo more aggressive oncological treatment. 
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